SWEETENING INGREDIENTS

Information

  • Patent Application
  • 20230084263
  • Publication Number
    20230084263
  • Date Filed
    February 15, 2021
    5 years ago
  • Date Published
    March 16, 2023
    3 years ago
  • CPC
  • International Classifications
    • A23L2/60
    • A23L33/135
    • A23L33/14
    • A23L33/105
Abstract
The present invention relates to ingredients, particularly sweetening ingredients, for example ingredients for use in reduced sugar, low-sugar, or zero-sugar beverage or food products. More specifically, the present invention relates to ingredients derived from plant infusions, in particular fermented infusions of stevia.
Description
FIELD OF THE INVENTION

The present invention relates to ingredients, particularly sweetening ingredients, for example ingredients for use in reduced sugar, low-sugar, or zero-sugar beverage or food products. More specifically, the present invention relates to ingredients derived from plant infusions, in particular infusions of stevia (e.g. Stevia rebaudiana).


BACKGROUND

The South American plant, Stevia rebaudiana, is known for its sweet-tasting leaves. The sweet taste comes from naturally occurring compounds within the stevia plant, called steviol glycosides. However, stevia can also taste bitter, have liquorice-like aromas, and sometimes metallic and astringent mouthfeels. These other sensory attributes of stevia are undesirable and limit its use as a sweetening ingredient in its natural form.


Sweetening ingredients and additives derived from, or based on, stevia, have previously been developed. A problem with many sweeteners derived from stevia is that they can still tend to have a liquorice aftertaste, which is undesirable to many consumers in terms of their taste in soft drinks. Another problem associated with stevia-derived sweeteners is that their taste can linger on the tongue for longer than the sugar temporal profile that consumers are accustomed to. This means that the application and market size for using these sweeteners is considerably limited.


The general approach, to address the limitations of the natural taste of stevia, has been to extract, isolate and/or concentrate the compounds responsible for the sweet taste, i.e. the steviol glycosides. These compounds are the main ingredients (or precursors) of many sweeteners marketed under the generic name ‘stevia’ and several trade names. More than 50 steviol glycosides have been found in S. rebaudiana leaves, including stevioside, steviolbioside, dulcoside A and many rebaudiosides. Steviol glycosides from Stevia rebaudiana have been reported to be between 30 and 350 times sweeter than sucrose. They are heat-stable, pH-stable, and are often described as being non-fermentable (see, e.g., Journal of Medicinal Plants Research; Vol. 7(46), pp. 3343-3353, 10 Dec. 2013). Additionally, they do not induce a glycemic response when ingested, because humans cannot metabolize steviol glycosides, which makes them attractive as natural sugar substitutes for diabetics and other people on carbohydrate-controlled diets (see, e.g., S.M. Savita et al (2004), Journal of Human Ecology, Vol. 15 (4), pp. 261-264). Steviol glycosides and related sweet molecules (e.g. diterpenic and triterpenic sweet molecules, such as the suaviosides and mogrosides) also occur in related species such as Stevia phlebophylla, in the plants Rubus chingii (Rosacae) and Rubus suavissimus (Chinese blackberry), and in the fruit of the gourd vine, luo han guo (Siraitia grosvenorii) or monk fruit.


In typical stevia leaves, up to over 95% of the steviol glycosides contain 1-4 glucose units. Steviol glycosides of higher glycosylation (>4 glucose units) have an improved taste but are present only at very low concentrations and so are significantly more expensive. Solvent extraction, currently used to isolate these more highly glycosylated glycosides, is not ideal given the large volumes of solvent being used and necessary number of purification steps. A number of companies utilise enzymes to glycosylate stevia extracts. However, enzymatically glycosylated steviol glycosides are not approved as sweeteners in the EU, and obtaining regulatory approval for use in food is not straightforward. Another approach has been to use recombinant (i.e. genetically modified) microorganisms such as bacteria and yeasts to produce desirable steviol glycoside compounds. However, many consumers would prefer to avoid products which involve the use of genetically modified organisms, so this is also not ideal.


There is therefore a need for alternative natural sweetening ingredients based on stevia, with superior taste credentials, wider consumer appeal and greater utility. The present invention has been devised in light of these considerations.


SUMMARY OF THE INVENTION

The present inventors have devised a novel and inventive approach to this problem, which focusses on stevia itself as a natural plant ingredient and uses natural processes to modify and improve its flavour and hence increase its utility as a sweetener. This is in direct contrast to the majority of approaches currently being pursued elsewhere, which are based on extracting or isolating particular chemical compounds from the stevia plant, or on producing those compounds synthetically.


The present invention accordingly provides a natural ingredient based on a fermented infusion of stevia. In some aspects the invention provides a natural ingredient comprising a fermented infusion of stevia.


The ingredient of the invention has a taste and sensory profile which is modified (improved) as a result of the fermentation (i.e. when compared to an unfermented stevia infusion). For example, undesirable flavour compounds, including those responsible for bitter liquorice notes and/or woody notes, and/or green, grassy, ‘tea-like’ flavours, may be reduced or absent. Furthermore, in some embodiments, certain flavour compounds may be present, enriched, or enhanced in the fermented infusion, which contribute to the improved taste.


In one aspect, the invention provides an ingredient, i.e. a sweetening ingredient, e.g. for a foodstuff or a beverage, comprising a fermented infusion of stevia, wherein the infusion has been fermented using a microorganism which is preferably yeast or bacteria or a combination thereof.


In these aspects, the yeast and/or bacteria may be selected, e.g. via a screening process, so as to produce a pre-determined sensory and/or taste profile in the final (fermented) product.


In another aspect, the invention provides an ingredient based on a fermented infusion of stevia, wherein the fermented infusion is obtainable by contacting stevia (e.g. fresh or dried stevia leaves) with water and heating to produce an infusion, then directly contacting a fermentation microorganism with said infusion (e.g. by adding the fermentation microorganism directly to said infusion).


In another aspect, the invention provides an ingredient, i.e. a sweetening ingredient, e.g. for a foodstuff or a beverage, comprising a fermented infusion of stevia, wherein the fermented infusion is prepared by contacting stevia (e.g. fresh or dried stevia leaves) with water and optionally heating to produce an infusion, then directly contacting a fermentation microorganism with said infusion (e.g. by adding the fermentation microorganism directly to said infusion).


In another aspect, the present invention provides an ingredient based on a fermented infusion of stevia, wherein the infusion has been fermented using a combination of at least two different microorganisms. In some embodiments, the infusion has been fermented using a combination of at least one yeast and at least one bacteria.


A further aspect of the present invention is an ingredient, for example a sweetening ingredient, comprising steviol glycosides in aqueous solution and having physicochemical properties, for example a pH, optical density, lactate and acetate content, as described herein.


In a further aspect, also provided is a solid ingredient, e.g. a sweetening ingredient, obtained by or obtainable by drying an ingredient as described herein. In some embodiments, the solid ingredient may be formulated, for example, as a granulated sweetener or a sweetening tablet.


In one aspect, the present invention provides a process for preparing an ingredient, i.e. a sweetening ingredient, comprising contacting stevia (e.g. fresh or dried stevia leaves) with water and heating to produce an infusion, then contacting a fermentation microorganism directly with said infusion (e.g. by adding the fermentation microorganism directly to said infusion).


For example, the process may comprise the steps of:


(a) contacting stevia (e.g. cut, native or dried stevia leaf) with water, preferably with heating to a temperature of 40-90° C., or at a temperature of 40-80° C., or at a temperature of 50-70° C., to produce an infusion;


(b) (optionally) adding a carbohydrate feedstock, preferably a sugar, to the infusion;


(c) (optionally) filtering the infusion to remove remaining stevia;


(d) contacting the infusion with a fermentation microorganism, e.g. by adding the fermentation microorganism to the infusion;


(e) fermenting the infusion under conditions suitable to the microorganism; and


(f) (optionally) filtering the fermented infusion to remove the microorganism.


Also provided by the present invention is an ingredient obtainable using a process as described herein. Also provided is an ingredient obtained using a process as described herein.


In some embodiments of the products and processes of the invention, the microorganism used to ferment the infusion is, or comprises, a yeast, for example a yeast of the family Saccharomycetaceae. In some embodiments the microorganism used for the fermentation is a yeast selected from: Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxianus, Zygosaccharomyces Pichia membranifaciens, Cyberlindnera jadinii, and Meyerozyma guilliermondii.


In some embodiments products and processes of the invention, the microorganism used to ferment the infusion is, or comprises a bacterium, for example a lactic-acid producing bacterium.


In some embodiments, more than one microorganism is used for the fermentation. For example, a combination of two or more yeasts, a combination of two or more bacteria, or a combination of one or more yeasts with one or more bacteria. In these embodiments, fermentation with more than one microorganism may take place sequentially or simultaneously.


In some embodiments, the microorganism used for the fermentation comprises a combination of one or more yeasts with one or more bacteria, wherein the yeast is preferably selected from Kluyveromyces lactis, Kluyveromyces marxianus, Zygosaccharomyces rouxii, Pichia membranifaciens, Cyberlindnera jadinii, and Meyerozyma guilliermondii, and wherein the bacterium is preferably of the Lactobacillus genus, and is more preferably selected from Lactobacillus delbrueckii, Lactobacillus fructivorans, and Lactobacillus acidophilus.


In a further aspect, the present invention provides the use of a sweetening ingredient as described herein in the production of a food or beverage product. Also provided is a food or beverage product, preferably a reduced sugar, low-sugar or sugar-free food or beverage product, comprising a sweetening ingredient as described herein.


The present invention expressly encompasses any combination of the aspects and preferred features described herein, except where such a combination is clearly impermissible or expressly avoided.





SUMMARY OF THE FIGURES

Embodiments and experiments illustrating the principles of the invention will now be discussed with reference to the accompanying figures:



FIG. 1. Sensory profile of fermented stevia infusion prepared in accordance with the invention (see Example 2; stevia infusions of varying strength fermented for 2 days using S. cerevisiae yeast). Results are compared to the unfermented stevia infusion. Modalities assessed include appearance (Ap), Aroma (Ar), Flavour (F), Aftertaste (At). FIG 1a shows profile for 1.2 g/L stevia (unfermented vs. fermented); FIG. 1 b shows profile for 5 g/L stevia (unfermented vs. fermented); FIG. 1c shows profile for 10 g/L stevia (unfermented vs. fermented).



FIG. 2. A, Base Peak Chromatogram (BPC) “fermented sample” (grey) vs “unfermented control”(black) (Example 7, Table 1, sample 10, HPLC method I) with intensity on y-axis over time on x-axis; B, MS-spectrum (intensity on the y-axis over m/z on x-axis) at the elution time of the peak of interest (marked with arrow); B1, MS-spectrum peak (RT 13 min); B2, MS-spectrum peak (RT 22.5 min).



FIG. 3. A, Base Peak Chromatogram (BPC) “fermented sample”(grey) vs “unfermented control”(black) (Example 7, Table 1, sample 07, HPLC method I) with intensity on y-axis over time on x-axis; B, MS-spectrum (intensity on the y-axis over m/z on x-axis) at the elution time of the peak of interest (marked with arrow); B1, MS-spectrum peak (RT 13 min); B2, MS-spectrum peak (RT 22.5 min).



FIG. 4. A, Base Peak Chromatogram (BPC) “fermented sample” (grey) vs “unfermented control” (black) (Example 7, Table 2, sample 05_06, HPLC method I) with intensity on y-axis over time on x-axis; B, MS-spectrum (intensity on the y-axis over m/z on x-axis) at the elution time of the peak of interest (marked with arrow); B1, MS-spectrum peak (RT 13 min); B2, MS-spectrum peak (RT 22.5 min).



FIG. 5. A, Base Peak Chromatogram (BPC) “fermented sample” (grey) vs “unfermented control” (black) (Example 7, Table 2, sample 07_08, HPLC method I) with intensity on y-axis over time on x-axis; B, MS-spectrum (intensity on the y-axis over m/z on x-axis) at the elution time of the peak of interest (marked with arrow); B1, MS-spectrum peak (RT 13 min); B2, MS-spectrum peak (RT 22.5 min). FIG. 6. A, Base Peak Chromatogram (BPC) “fermented sample” (grey) vs “unfermented control” (black) (Example 7, Table 1, sample 19, HPLC method I) with intensity on y-axis over time on x-axis; B, MS-spectrum (intensity on the y-axis over m/z on x-axis) at the elution time of the peak of interest (marked with arrow); B1, MS-spectrum peak (RT 13 min); B2, MS-spectrum peak (RT 22.5 min).



FIG. 7. Full sensory profiles (trained panel) of fermented stevia infusions prepared in accordance with the invention. See Example 7; Table 1; Samples 10 (dashed line) and 19 (dotted line). Results are compared to a non-fermented reference sample (Ref; solid line). Modalities assessed include appearance (Ap), Aroma (Ar), Flavour (F), Mouthfeel (Mf), Aftertaste (At). Boxed attributes show statistically significant differences at 95% confidence.



FIG. 8. A, Base Peak Chromatogram (BPC) “fermented sample” (grey) vs “unfermented control” (black) (Example 7B, sample S015B; HPLC method II) with intensity on y-axis over time on x-axis; B, MS-spectrum (intensity on the y-axis over m/z on x-axis) at the elution time of the peak of rubusoside standard (marked with arrow).



FIG. 9. Sensory results from shortbread tasting. Results for attributes appearance, overall flavour, sweetness, bitterness, overall texture, crispiness and lingering aftertaste (AT) are shown in a spider diagram. Shortbreads A (full sugar), B (half sugar+fermented stevia infusion of the invention), C (half sugar +unfermented stevia infusion), and D (half sugar+Reb A) were compared.



FIG. 10. Exemplary stevia infusion step, using continuous flow column. Stevia (8 kg) is covered with hot water (80° C.) in the column (initial volume 65 L). Further water is added continuously during an initial soaking step (˜15 mins) and a subsequent elution step where the valve at the base of the column is opened to run off the infusion (over a further ˜35 minutes). Total volume of hot water used =130 L. Total infusion time =50 mins. Final infusion volume collected =80 L.





DETAILED DESCRIPTION OF THE INVENTION

Aspects and embodiments of the present invention will now be discussed with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.


Described herein is an ingredient, for example a sweetening ingredient based on, or comprising, a fermented infusion of stevia.


The term ‘stevia’ as used herein refers primarily to plant material from stevia (i.e. Stevia rebaudiana). Alternative plant materials may include those from related plants including, but not limited to, Stevia phlebophylla, Rubus chingii (Rosacae), Rubus suavissimus (Chinese blackberry), and monk fruit (Siraitia grosvenorii). Unless otherwise specified, the term ‘stevia’ as used herein expressly includes these related plants (i.e. plants comprising diterpenic and triterpenic sweet compounds, such as steviol glycosides, mogrosides and suavosides). Plant material includes, without limitation, the leaf, bark, vine, stem, seed, bean, nut, sap, oil, milk, bud, fruit, berry, root and/or flower. In preferred embodiments, the plant material comprises leaf. In some embodiments, the plant material may comprise waste plant material, for example pomace, which includes skins, pulp, seeds or stems or waste leaves. The plant material may comprise fresh plant material (e.g. fresh leaves) or dried plant material (e.g. dried leaves). It may be cut or chopped if desired, or used whole (e.g. whole leaves). Preparations of stevia plant material suitable for use in the present invention (for example, dried stevia leaves) are readily available e.g. from commercial sources.


In some embodiments, the stevia used in the processes and products of the invention comprises stevia leaves.


In some embodiments, the stevia used in the processes and products of the invention comprises dried stevia (e.g. dried stevia leaves). Dried stevia is stevia plant material (e.g. leaves) from which water has been removed, for example using methods known in the art (e.g. air drying, convective drying, freeze drying). Dried leaves, as used herein can be distinguished from cured leaves, which are treated under specific conditions (a curing process), which may remove water but which also chemically modify the plant material itself. In some embodiments of the present invention the stevia plant material, as supplied, is not chemically processed (e.g. by curing) before use.


In some embodiments, the stevia used in the processes and products of the invention comprises uncured stevia leaves. In some embodiments, the stevia used in the processes and products of the invention comprises dried, uncured stevia leaves.


In some embodiments, the stevia used in the processes and products of the invention comprises cut stevia e.g. cut stevia leaves. Preferably, cutting is carried out using a blade or knife (rather than, for example, a mesh or grinder). Preferably the leaves are not cut too finely. Without wishing to be bound by theory, in some embodiments it may be preferable to avoid excessively fine particles of stevia (e.g. dust or powder). Preferably, the stevia used in the processes and products of the invention is not ground, powdered or pulverised.


In some embodiments, the stevia used in the processes and products of the invention comprises cut stevia leaves. In some embodiments, the stevia used in the processes and products of the invention comprises cut, dried stevia leaves. In some embodiments, the stevia used in the processes and products of the invention comprises cut, uncured stevia leaves. In some embodiments, the stevia used in the processes and products of the invention comprises cut, dried, uncured stevia leaves. In some embodiments, the stevia leaves are cut to a size (i.e. a median diameter) of between about 1 mm and about 10 mm.


The ingredient of the present invention is based on an infusion of stevia. The term ‘infusion’ is commonly used, e.g. in the beverage industry, to refer to a drink made by soaking tea leaves, herbs, etc. in liquid, preferably water. More generally, and as used herein, the term ‘infusion’ refers to a liquid composition obtained by contacting plant material (i.e. stevia plant material as described herein) with water, preferably at an elevated temperature.


Preferably, the infusion is produced at a temperature below boiling point (i.e. below 100° C.) such that organic compounds from the plant material (e.g. the flavour and aroma compounds including, but not limited to, steviol glycosides) are gently dissolved into the water. This can be distinguished from methods used in the prior art to produce ‘extracts’ of stevia, wherein the plant material is e.g. boiled vigorously in water and/or other solvent(s), sometimes repeatedly i.e. over multiple extraction steps, and is often then further concentrated e.g. in vacuo, to maximise the yield of organic compounds removed from the plant. The infusions used in the present invention are distinct from these highly concentrated ‘extracts’ of stevia.


Methods and processes for producing infusions of stevia for use in the present invention are further described below.


To produce an ingredient, e.g. a sweetening ingredient, according to the present invention, the infusion of stevia may be subject to a fermentation step. Fermentation can be generally defined as a metabolic process in which a microorganism (e.g. a yeast, a fungus or bacteria; either active cells or resting cells) converts carbohydrate (i.e. starch or sugar) into alcohol or acids and/or carbon dioxide. Fermentative modification of other organic compounds present in the substrate (fermentation medium) occurs concurrently, resulting in further changes to the chemical composition of the substrate. The term ‘fermented’ as used in the context of food and beverage products has been defined by the Food and Agriculture Organisation of the United Nations (see: http://www.fao.org/biotech/C11doc.htm) as the process of bioconversion of organic substances by microorganisms and/or enzymes (complex proteins) of microbial, plant or animal origin. The term ‘fermented’ as used herein may be construed accordingly. In particular embodiments however it may refer, more specifically, to a product which has been subjected to a fermentation process by inoculation with a suitable microorganism, preferably in the presence of a suitable carbohydrate feedstock.


Fermentation methods and processes, suitable for use in the present invention, are further described below.


The ingredient of the invention has a taste and sensory profile which is modified (improved) as a result of the fermentation process (i.e. when compared to an unfermented stevia infusion). Surprisingly and advantageously, the present inventors have found that an improved taste and sensory profile can be obtained by subjecting an infusion of stevia (e.g. an infusion of stevia leaf) to a natural fermentation process i.e. by adding a fermentation microorganism such as yeast or bacteria to the infusion and then fermenting under appropriate conditions. For example, undesirable flavour compounds, including those responsible for bitter liquorice notes and/or woody notes and/or green, grassy, ‘tea-like’ flavours may be reduced or eliminated from the fermented infusion. In some embodiments, the fermented infusion has reduced bitter liquorice flavours; in some embodiments, the fermented infusion has reduced woody flavours; and/or in some embodiments the fermented infusion has reduced green/grassy flavours; when compared to an unfermented stevia infusion.


In some embodiments the amount of certain volatile compounds including, but not limited to, terpenoids such as alpha-pinene, beta-bourbonene, alpha-bergamotene, and spathulenol, may be decreased in the infusion after fermentation.


In some embodiments the amount of certain volatile compounds including, but not limited to ethanol, 2-methyl-1-propanol, 3-methylbutanal, 2-methylbutanol, 3-methylbutyric acid, 2-methylbutyric acid, 3-methylbutyl acetate, 2-methylbutyl acetate, butoxyacetic acid, benzaldehyde, ethyl hexanoate, benzenacetaldehyde, alpha-dimethylstyrene, benzeneethanol, octanoic acid, ethyl octanoate, nonanoic acid, decanoic acid, beta-damascenone, 9-decenoic acid, and ethyl decanoate may be increased in the infusion after fermentation.


Furthermore, in some embodiments, certain flavour compounds, which contribute to the improved taste, may be present in the fermented infusion and/or may be enhanced or increased in the fermented infusion. In other words, fermentation of the infusion may shift or alter the composition of the stevia infusion, when compared to the composition before fermentation. Without wishing to be bound by theory, it is thought that, in some embodiments, the relative proportions of particular steviol glycosides and/or related compounds, having flavour-enhancing properties, may be increased by fermentation. In some embodiments, surprisingly, the relative proportions of steviol glycoside compounds are substantially unchanged, but the sensory profile is nevertheless significantly modified and/or improved. Without wishing to be bound by theory this is thought to be primarily as a result of other changes in the composition resulting from the inventive fermentation process.


In some embodiments, changes in the composition of in the fermented infusion are indicated by the presence of novel markers in a spectroscopic analysis, for example in an LC-MS spectrum. For example, the present inventors have noted that, in some embodiments of the present invention, new peaks having m/z 1127 and m/z 701 are detected in the fermented infusion, which are not found (i.e. are below detectable limits) in an unfermented stevia infusion (mass spectrometric detection using a Bruker AmazonSL lonTrap in negative mode, scan range 500-1200 m/z). The peaks are detected at RT 13 min and 23 min respectively (LC-MS using a Phenomenex Synergi column: 2.5 μ Hydro-RP 100 A, 100*2; Solvent A: 0.04% acetic acid; Solvent B: methanol +0.04% acetic acid; Flow: isocratic 50%B with 0.25 ml/min).


Without wishing to be bound by theory, it is thought that these peaks may represent steviol glycosides or related compounds which are produced, enriched, or enhanced by the fermentation reaction. In some embodiments of the present invention, therefore, the sweetening ingredient described herein comprises a fermented infusion of stevia comprising at least one steviol glycoside compound with a molecular weight of about 1128 (corresponding to m/z 1127 in negative mode) which was not detected in the unfermented infusion. In some embodiments, the sweetening ingredient comprises a fermented infusion of stevia comprising at least one steviol glycoside compound with a molecular weight of about 702 (corresponding to m/z 701 in negative mode) which was not detected in the unfermented infusion.


The present inventors have also found that in some embodiments, the relative proportion of certain steviol glycoside compounds, in particular of Rubusoside, may be increased by the fermentation process. Without wishing to be bound by theory, since Rubusoside has fewer sugar (glycoside) units compared to the other steviol glycosides such as RebA and RebG it is possible that, in these embodiments, some of these steviol glycosides have been converted to Rubusoside during the fermentation process.


In some embodiments, the weight ratio of Rubusoside to the sum of Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Stevioside, Rebaudioside F, Rebaudioside M, Rebaudioside N, Dulcoside A, Rebaudioside I, Rebaudioside G, Rubusoside, Steviobioside and Rebaudioside E in the sweetening ingredient of the invention is from about 0.5% to about 15%, about 1.0% to about 15%, about 1.5% to about 15%, about 2.0% to about 15%, about 2.5% to about 15%, about 3.0% to about 15%, about 3.5% to about 15%, about 4.0% to about 15%, about 4.5% to about 15%, about 5.0% to about 15%, about 5.5% to about 15%, about 6.0% to about 15%, about 6.5% to about 15%, about 0.5% to about 14%, about 0.5% to about 13%, about 0.5% to about 12%, about 0.5% to about 11%, about 0.5% to about 10%, about 0.5% to about 9.5%, about 0.5% to about 9.0%, about 0.5% to about 8.5%, about 0.5% to about 8.0%, about 1.0% to about 14%, about 1.5% to about 13%, about 2.0% to about 12%, about 2.5% to about 11%, about 3.0% to about 10%, about 3.5% to about 9.5%, or about 4.0% to about 9.0%.


In some embodiments, the mole ratio of Rubusoside to sum of Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Stevioside, Rebaudioside F, Rebaudioside M, Rebaudioside N, Dulcoside A, Rebaudioside I, Rebaudioside G, Rubusoside, Steviobioside and Rebaudioside E in the sweetening ingredient of the invention is from about 0.5% to about 15%, about 1.0% to about 15%, about 1.5% to about 15%, about 2.0% to about 15%, about 2.5% to about 15%, about 3.0% to about 15%, about 3.5% to about 15%, about 4.0% to about 15%, about 4.5% to about 15%, about 5.0% to about 15%, about 5.5% to about 15%, about 6.0% to about 15%, about 6.5% to about 15%, about 0.5% to about 14%, about 0.5% to about 13%, about 0.5% to about 12%, about 0.5% to about 11%, about 0.5% to about 10%, about 1.0% to about 14%, about 1.5% to about 13%, about 2.0% to about 12%, about 2.5% to about 11%, or about 3.0% to about 10%.


Advantageously, the present inventors have found that, by appropriate selection of fermentation microorganism(s) and optimisation of process conditions, it is possible to produce a fermented infusion matching a target profile. In some embodiments, the target profile comprises a pre-determined sensory and/or taste profile. In some embodiments, the target profile comprises (additionally or alternatively) pre-determined analytical criteria. Analytical criteria may include, for example, the presence or absence of certain compounds in the composition, or a particular ratio of certain components, such as particular steviol glycoside compounds, which may be assessed by spectroscopic methods. More broadly, analytical criteria may include, for example, the presence or absence of certain spectroscopic markers, e.g. the presence or absence of certain peaks in an LC-MS spectrum.


In some embodiments, analytical criteria indicative of a target sensory profile may include the pH of the fermented infusion, as further described below. In some embodiments, analytical criteria indicative of a target sensory profile may include the optical density of the fermented infusion, as further described below. In some embodiments, analytical criteria indicative of a target sensory profile may include the content or concentration of one or more metabolites including, but not limited to, lactate and acetate, as further described below.


The sweetening ingredients described herein comprise a fermented infusion of stevia, wherein the fermented infusion is preferably obtainable by, or obtained by: contacting stevia (e.g. dried stevia leaves) with water and heating, then contacting/adding a fermentation microorganism directly with/to said infusion.


Processes for preparing the sweetening ingredients of the present invention are generally described herein. For example, the process may comprise the steps of:


(a) contacting stevia with water, and preferably heating, to produce an infusion;


(b) (optionally) adding a carbohydrate (e.g. a sugar) or a carbohydrate source to the infusion;


(c) (optionally) filtering the infusion to remove remaining stevia;


(d) contacting the infusion with a fermentation microorganism (e.g. adding said fermentation microorganism to the infusion); (e) fermenting the infusion under conditions suitable to the microorganism; and (f) (optionally) filtering the fermented infusion.


The labels (a) to (f) above are not to be regarded as limiting. As would be understood by the person skilled in the art, the steps may be carried out in any technically reasonable order. It will also be understood that despite being written as separate ‘steps’, in some embodiments certain actions may be performed simultaneously. For example, as explained further below, in some embodiments, carbohydrate may be added to the infusion along with the fermentation microorganism (e.g. pre-activated yeast).


The infusion step (i.e. step (a) in the above example) comprises contacting (i.e. mixing, combining) the stevia plant material with water and, preferably, heating.


In some embodiments, the infusion step comprises heating to a temperature above about 40° C. In some embodiments, the infusion step comprises heating to a temperature above about 50° C. In some embodiments, the infusion step comprises heating to a temperature above about 60° C.


In some embodiments, the infusion step comprises heating to a temperature below about 100° C. In some embodiments, the infusion step comprises heating to a temperature below about 90° C. In some embodiments, the infusion is heated to a temperature below about 85° C. In some embodiments, the infusion is heated to a temperature below about 80° C. In some embodiments, the infusion is heated to a temperature below about 70° C.


In some embodiments the temperature is about 40-90° C. In some embodiments the temperature is about 40-85° C. In some embodiments the temperature is about 50-90° C. In some embodiments the temperature is about 40-90° C. In some embodiments the temperature is about 50-85° C. In some embodiments the temperature is about 40-80° C. In some embodiments the temperature is about 50-80° C. In some embodiments the temperature is about 40-70° C. In some embodiments the temperature is about 50-70° C. In some embodiments the temperature is about 60° C. In some embodiments the temperature is about 70° C. In some embodiments the temperature is about 80° C.


In some embodiments, the duration of the infusion step — i.e. the length of time during which the stevia plant material is in contact with the (hot) water: the ‘steep’ time—is less than about 120 minutes. In some embodiments, the duration of the infusion step is less than about 90 minutes. In some embodiments, the duration of the infusion step is less than about 75 minutes. In some embodiments, the duration of the infusion step is less than about 60 minutes. In some embodiments, the duration of the infusion step is less than about 45 minutes. In some embodiments, the duration of the infusion step is less than about 30 minutes.


In some embodiments, the duration of the infusion step is longer than about 10 minutes. In some embodiments, the duration of the infusion step is longer than about 15 minutes. In some embodiments, the duration of the infusion step is longer than about 20 minutes.


In some embodiments, the duration of the infusion step is from 10 to 75 minutes. In some embodiments, the duration of the infusion step is from 15 to 60 minutes. In some embodiments, the duration of the infusion step is from 30 to 60 minutes. In some embodiments, the duration of the infusion step is from 15 to 45 minutes. In some embodiments, the duration of the infusion step is from 30 to 45 minutes. In some embodiments, the duration of the infusion step is about 30 minutes.ln some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) greater than about 15 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) greater than about 20 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) greater than about 30 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) greater than about 60 g/L.


In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) lower than about 180 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) lower than about 150 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) lower than about 120 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) lower than about 100 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) lower than about 90 g/L.


In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) between about 15 g/L and about 150 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) between about 15 g/L and about 100 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) between about 15 g/L and about 90 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) between about 20 g/L and about 100 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) between about 20 g/L and about 90 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) between about 20 g/L and about 60 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) between about 20 g/L and about 50 g/L. In some embodiments, the infusion is produced by mixing stevia with water at a concentration (w/v) between about 20 g/L and about 50 g/L.


In some embodiments, the infusion may be produced in a continuous column process (see FIG. 10) with an initial volume of water (optionally heated as described above) being added to cover the stevia for an initial soaking step and the remaining volume of water being added during a second extraction step wherein the infusion is collected from the bottom of the column. In such embodiments the concentration (w/v) as set out above may be calculated relative to the total volume of water used.


Additional water may be added to the infusion prior to the fermentation step (for example, along with the microorganism or in a separate step, e.g. to top-up evaporated water after infusion or to dilute the infusion to a desired concentration). The concentrations above refer to the amount of stevia plant material present during the ‘steep’ (infusion process).


In some embodiments, at least one carbohydrate is preferably added to the stevia infusion, to be used by the microorganism(s) as a carbon source during the fermentation reaction. The carbohydrate preferably comprises a sugar, for example: glucose, sucrose, fructose, lactose, or any combination thereof. Other carbohydrates include, but are not limited to, starch, cellulose, hemicelluloses, pectin, inulin, pullulan and saccharose. In some embodiments, a carbohydrate is not added but a source of carbohydrate may be added to produce a feedstock for the fermentation in situ. For example, fibre may be converted to sugars by an added enzyme, such as a cellulase.


The carbohydrate or carbohydrate source may conveniently be added to the water along with the stevia plant material, before or during the infusion process. Some or all of the carbohydrate may also be added to the microorganism, prior to its addition to the infusion. For example, in particular when the microorganism is a yeast, some sugar may be used to ‘activate’ the yeast, prior to its addition to the infusion.


The total amount of carbohydrate added to the infusion (i.e. the amount of carbohydrate present at the start of the fermentation step) is preferably more than about 2 g/L. In some embodiments, the total amount of carbohydrate added to the infusion (i.e. the amount of carbohydrate present at the start of the fermentation step) is preferably more than about 4 g/L. In some embodiments, the total amount of carbohydrate added to the infusion (i.e. the amount of carbohydrate present at the start of the fermentation step) is preferably more than about 5 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is more than about 10 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is more than about 15 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is more than about 20 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is more than about 25 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is equal to or more than about 30 g/L.


The total amount of carbohydrate added to the infusion (i.e. the amount of carbohydrate present at the start of the fermentation step) is preferably less than about 60 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is less than about 50 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is less than about 40 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is less than about 35 g/L.


In some embodiments, the total amount of carbohydrate added to the infusion is from 2 g/L to 50 g/L.


In some embodiments, the total amount of carbohydrate added to the infusion is from 2 g/L to 35 g/L.


In some embodiments, the total amount of carbohydrate added to the infusion is from 5 g/L to 50 g/L.


In some embodiments, the total amount of carbohydrate added to the infusion is from 10 g/L to 40 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is from 20 g/L to 50 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is from 20 g/L to 40 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is from 30 g/L to 50 g/L. In some embodiments, the total amount of carbohydrate added to the infusion is about 30 g/L.


In preferred embodiments, the carbohydrate feedstock used is a sugar. In some embodiments, the sugar is selected from glucose and sucrose. In some embodiments, the sugar is sucrose.


The total amount of sugar added to the infusion (i.e. the amount of sugar present at the start of the fermentation step) is preferably more than about 5 g/L (0.5 Bx). In some embodiments, the total amount of sugar added to the infusion is more than about 10 g/L (1 Bx). In some embodiments, the total amount of sugar added to the infusion is more than about 15 g/L (1.5 Bx). In some embodiments, the total amount of sugar added to the infusion is more than about 20 g/L (2 Bx). In some embodiments, the total amount of sugar added to the infusion is more than about 25 g/L (2.5 Bx). In some embodiments, the total amount of sugar added to the infusion is equal to or more than about 30 g/L (3 Bx).


The total amount of sugar added to the infusion (i.e. the amount of sugar present at the start of the fermentation step) is preferably less than about 60 g/L (6 Bx). In some embodiments, the total amount of sugar added to the infusion is less than about 50 g/L (5 Bx). In some embodiments, the total amount of sugar added to the infusion is less than about 40 g/L (413x). In some embodiments, the total amount of sugar added to the infusion is less than about 35 g/L (3.5 Bx).


In some embodiments, the total amount of sugar added to the infusion is from 5 g/L (0.5 Bx) to 50 g/L (5 Bx). In some embodiments, the total amount of sugar added to the infusion is from 10 g/L (1 Bx) to 40 g/L (4 Bx). In some embodiments, the total amount of sugar added to the infusion is from 20 g/L (2 Bx) to 50 g/L (5 Bx). In some embodiments, the total amount of sugar added to the infusion is from 20 g/L (2 Bx) to 40 g/L (4 Bx). In some embodiments, the total amount of sugar added to the infusion is from 30 g/L (3 Bx) to 50 g/L (5 Bx). In some embodiments, the total amount of sugar added to the infusion is about 30 g/L (3 Bx).


In some embodiments, the infusion is filtered to remove the stevia plant material (i.e. the stevia leaves), before the fermentation microorganism is added. In alternative embodiments, the plant material may be removed by other known methods such as e.g. centrifugation or decantation, References herein to filtration are intended to encompass also these methods, where appropriate. In other embodiments, the fermentation microorganism is added directly to the infusion without filtering: in some embodiments the plant material may then be removed at a later stage, along with other unwanted solids (e.g. biomass from the fermentation microorganism).


Processes for producing ingredients according to the present invention may comprise a step wherein a stevia infusion, produced as described above, is fermented using a microorganism. To start the fermentation process, a suitable microorganism (or preparation thereof) is added to the stevia infusion.


Preferably, the microorganism is added directly to the liquid product from the infusion step (after filtration and/or cooling, if applicable). Preferably, the stevia infusion prepared as set out above is used directly in the fermentation step which follows, except that in some embodiments the infusion may be filtered to remove stevia plant material and/or in some embodiments it may be diluted by the addition of further liquid (water) and/or in some embodiments it may be cooled (e.g. for temporary storage) and/or heated to an appropriate fermentation temperature. In particular, in preferred embodiments, the stevia infusion is not subjected to any chemical modification, solvent extraction, or concentration steps, prior to fermentation.


In some embodiments, additional water may be added, either separately or along with the microorganism (e.g. as part of a preparation of the microorganism). In some embodiments, the microorganism is added in a liquid preparation comprising additional water. In some embodiments, the microorganism is added in a liquid preparation comprising water and some or all of the sugar required for the fermentation.


In some embodiments of the invention, the microorganism is, or comprises, a fungus selected from: Aspergillus spp.; Ustilago spp.; or a combination thereof. In some of the embodiments, the microorganism used for fermentation comprises one or more fungi selected from: Aspergillus oryzae, Ustilago maydis; or a combination thereof.


In some embodiments of the invention, the microorganism used to ferment the infusion is, or comprises, a yeast, for example a yeast of the family Saccharomycetaceae.


In some embodiments of the invention, the microorganism is, or comprises, a yeast selected from: Saccharomyces spp.; Pichia spp.; Zygosaccharomyces spp.; Kluyveromyces spp.; Kloeckera spp.; Brettanomyces spp.; Metschnikowia spp.; Aureobasidium spp.; Issatchenkia spp.; Torulaspora spp.; Lachancea spp.; Hanseniaspora spp.; Cyberlindnera spp.; and Meyerozyma spp.or a combination thereof. In some embodiments, the microorganism is a yeast selected from Saccharomyces spp.; Kluyveromyces spp.; Zygosaccharomyces spp.; Pichia spp.; Cyberlindnera spp.; and Meyerozyma spp.; or a combination thereof.


In some embodiments, the microorganism is, or comprises, a yeast selected from: S. cerevisiae; S. uvarum; S. bayanus; S. exiguus; S. carlsbergensis; T. delbrueckii; Lachancea thermotolerans; P. anomala; P. kluyveri; P. caribbica; P. guilliermondii; Z. bailii; K. marxianus; K. lactis; M. pulcherrima; A. pullulans, I. orientalis; K. apiculata; K. javanica; H. uvarum; H. osmophilia; or a combination thereof.


In some embodiments, the microorganism used for the fermentation comprises one or more yeasts selected from: Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxianus, Zygosaccharomyces rouxii, Pichia membranifaciens, Cyberlindnera jadinii, and Meyerozyma guilliermondii. In some embodiments, the microorganism used for the fermentation comprises one or more yeasts selected from: Zygosaccharomyces rouxii, Cyberlindnera jadinii, and Meyerozyma guilliermondii. In some embodiments, the microorganism used for the fermentation is, or comprises, Meyerozyma guilliermondii.


In some embodiments of the invention, the microorganism used to ferment the infusion is, or comprises, a bacterium, for example a lactic-acid producing bacterium.


In some embodiments of the invention, the microorganism used for the fermentation is, or comprises, bacteria, for example a lactic-acid producing bacteria, for example selected from the genera Lactobacillus (for example L. acidophilus or L. fructivorans), Leuconostoc, Pediococcus, Lactococcus (for example L. raffinolactis), Streptococcus, Aerococcus, Carnobacterium, Enterococcus, Oenococcus, Sporolacto bacillus, Tetragenococcus, Vagococcus, or Weissella. In other embodiments, the bacteria used for fermentation is selected from Zymomonas spp., preferably Z. mobilis; or Bacillus spp, for example B. stearothermophilus or B. licheniformis.


In some embodiments of the invention, the microorganism used for the fermentation is, or comprises, bacteria from the genus Lactobacillus. In some embodiments, the microorganism used for the fermentation is, or comprises, bacteria selected from L. acidophilus, L. fructivorans, L. gasseri, L. jensenii, L. delbrueckii, L. delbrueckii subsp. Bulgaricus, L. amylovorus, L, crispatus, and L. helveticus. In some embodiments, the microorganism used for the fermentation is, or comprises, Lactobacillus acidophilus, Lactobacillus fructivorans, and Lactobacillus delbrueckii. In some embodiments, the microorganism used for the fermentation is, or comprises, Lactobacillus acidophilus.


In some embodiments, more than one microorganism is used for the fermentation. For example, a combination of two or more yeasts; a combination of two or more bacteria; a combination of two or more fungi; a combination of one or more fungi with one or more bacteria; a combination of one or more yeasts with one or more fungi; or a combination of one or more yeasts with one or more bacteria.


In particular embodiments, the microorganism used for the fermentation comprises a combination of one or more yeasts with one or more bacteria, wherein the yeast is preferably selected from Kluyveromyces lactis, Kluyveromyces marxianus, Zygosaccharomyces rouxii, Pichia membranifaciens, Cyberlindnera jadinii, and Meyerozyma guilliermondii, and wherein the bacteria is preferably of the Lactobacillus genus, and is more preferably selected from Lactobacillus delbrueckii, Lactobacillus fructivorans, and Lactobacillus acidophilus.


In some embodiments, the microorganism used for the fermentation comprises a combination of a yeast selected from Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxianus, Zygosaccharomyces rouxii, Pichia membranifaciens, Cyberlindnera jadinii, and Meyerozyma guilliermondii, with at least one bacteria, preferably a lactic-acid producing bacterium as set out above.


In some embodiments, the microorganism used for the fermentation comprises a combination of a yeast and at least one lactic-acid producing bacteria, for example a bacteria selected from L. acidophilus, L. fructivorans, L. gasseri, L. jensenii, L. delbrueckii, L. delbrueckii subsp. Bulgaricus, L. amylovorus, L, crispatus, and L. helveticus, preferably selected from Lactobacillus acidophilus, Lactobacillus fructivorans, and Lactobacillus delbrueckii.


In these embodiments, fermentation with more than one microorganism may take place separately, sequentially or simultaneously.


In some embodiments, fermentation with more than one microorganism takes place simultaneously. For example, in some embodiments two or more yeasts are added, together, to the stevia infusion and fermentation by each occurs concurrently. In other embodiments, one or more yeasts and one or more bacteria are added together to the stevia infusion (dual inoculum) and fermentation by each occurs concurrently.


In some embodiments, fermentation with more than one microorganism takes place sequentially. For example, fermentation may be carried out first with one or more yeasts and, subsequently, further fermentation may be carried out with one or more bacteria. Alternatively, fermentation may be carried out first with one or more bacteria and, subsequently, further fermentation may be carried out with one or more yeasts.


An advantageous feature of the present invention is that, depending on the choice of microorganism(s) and on the process conditions used, a variety of different ingredients, e.g. sweetening ingredients, having different properties (including but not limited to sensory properties such as taste, appearance, aroma and mouthfeel) are accessible from the stevia plant material.


Microorganisms suitable for use in the present invention are generally described herein. In some embodiments of the invention, a suitable microorganism or combination of microorganisms for use in the fermentation process may be selected via a screening process. Such a screening process may assist in identifying species and/or strains of microorganisms which are capable of producing particular desired endpoints. For example, screening may be used to identify microorganisms which are capable of producing particular flavours and/or of removing particular flavours which are present in unfermented stevia. Alternatively or additionally screening may be used to identify microorganisms which are capable of producing, enriching or enhancing particular compounds (e.g. particular steviol glycosides and/or particular volatiles) in the fermentation reaction and/or of removing (i.e. degrading or chemically modifying) other compounds which are present in unfermented stevia.


Accordingly, in some embodiments of the present invention, the microorganism used in the fermentation step is selected so as to match a particular target profile in the final product. In some embodiments of the present invention, the microorganism used in the fermentation step is selected so as to produce a pre-determined sensory and/or taste profile in the final product. In some embodiments of the present invention, the microorganism used in the fermentation step is selected so as to produce a pre-determined analytical/chemical profile in the final product.


Such a screening process may, for example, comprise performing one or more test fermentation(s) on a suitable stevia infusion (e.g. by following a process such as that described herein) and performing analytical and/or sensory tests (as are well known in the art) on the resulting fermented samples, to determine whether, or to what extent, the analytical and/or sensory profile obtained corresponds to the pre-determined targets.


The fermentation step is carried out under conditions suitable for the microorganism(s) used, as is understood in the art.


In some embodiments, the fermentation step may be batch, fed-batch or continuous.


In some embodiments, the fermentation may be performed under substantially anaerobic conditions.


In some embodiments, the fermentation may be performed under substantially aerobic conditions.


In some embodiments, before addition to the stevia infusion the microorganism may be activated. In some embodiments, in particular when the microorganism is a yeast, activation comprises mixing the microorganism with water and, preferably, adding a suitable amount of sugar, in order to start the metabolic process of fermentation in the microorganism.


The resulting preparation of the microorganism (i.e. microorganism plus water, plus sugar if applicable) is added directly to the stevia infusion, to start the fermentation step of the process described herein. Any water and sugar included in this preparation contribute to the overall water and sugar content of the stevia infusion, as noted elsewhere, and hence form part of the fermentation medium.


In some embodiments, for activation purposes, sugar is added to the microorganism in a ratio from about 10:1 to about 50:1 (sugar/yeast w/w). In some embodiments, sugar is added to the microorganism in a ratio from about 15:1 to about 35:1 w/w. In some embodiments, sugar is added to the microorganism in a ratio from about 20:1 to about 30:1 w/w. In some embodiments, sugar is added in a ratio of about 25:1 w/w.


In some embodiments, the fermentation microorganism is present in an amount of at least about 0.1 g/L in the infusion (fermentation medium). In some embodiments, the fermentation microorganism is present in an amount of at least about 0.2 g/L. In some embodiments, the fermentation microorganism is present in an amount of at least about 0.3 g/L. In some embodiments, the fermentation microorganism is present in an amount of at least about 0.4 g/L. In some embodiments, the fermentation microorganism is present in an amount of about 0.4 g/L in the fermentation medium. In some embodiments, the fermentation microorganism is present in an amount of no more than about 0.6 g/L in the fermentation medium. In some embodiments, the fermentation microorganism is present in an amount of no more than about 0.8 g/L. In some embodiments, the fermentation microorganism is present in an amount of no more than about 1 g/L. In some embodiments, the fermentation microorganism is present in an amount of no more than about 2 g/L.


In some embodiments, the fermentation step is performed at a temperature of between 15° C. and 40° C. In some embodiments, the fermentation step is performed at a temperature of between 20° C. and 35° C. In some embodiments, the fermentation step is performed at a temperature of between 25° C. and 30° C. In some embodiments, the fermentation step is performed at a temperature of between 26° C. and 28° C. In some embodiments, the fermentation step is performed at a temperature below 35° C. In some embodiments, the fermentation step is performed at a temperature below 32° C. In some embodiments, the fermentation step is performed at a temperature below 30° C. In some embodiments, the fermentation step is performed at a temperature above 15° C. In some embodiments, the fermentation step is performed at a temperature above 20° C. In some embodiments, the fermentation step is performed at a temperature above 25° C.


In some embodiments, the duration of the fermentation is at least 2 hours. In some embodiments, the duration of the fermentation is at least 4 hours. In some embodiments, the duration of the fermentation is at least 24 hours. In some embodiments, the duration of the fermentation is at least 48 hours. In some embodiments, the duration of the fermentation is at least 72 hours (3 days). In some embodiments, the duration of the fermentation step may be less than 14 days. In some embodiments, the duration of the fermentation step may be less than 10 days. In some embodiments, the duration of the fermentation step may be less than 7 days. In some embodiments, the duration of the fermentation step may be less than 5 days. In some embodiments, the duration of the fermentation step may be less than 4 days.


In some embodiments, the duration of the fermentation step is about 1 day. In some embodiments, the duration of the fermentation step is about 2 days. In some embodiments, the duration of the fermentation step is about 3 days.


In some embodiments of the invention, the duration of fermentation is determined by the consumption of the carbohydrate feedstock (i.e. the sugar). This can be monitored by methods which are known in the art. The aim is to reduce the sugar level in the infusion (the fermentation medium) to zero, or as close as possible to zero.


Accordingly, in some embodiments, fermentation is continued until the added carbohydrate is completely, or almost completely, consumed. For example, the residual carbohydrate/sugar content after fermentation may be less than 25 g/L, less than 20 g/L, less than 15 g/L, less than 10 g/L, less than 5 g/L, less than 2 g/L, or less than 1 g/L. In some embodiments, at least 5 g/L sugar, at least 10 g/L sugar, preferably at least 15 g/I sugar, most preferably at least 20 g/L sugar is consumed by the microorganism during the fermentation reaction. In preferred embodiments, after fermentation, the infusion is substantially free of sugar. Accordingly, in some embodiments, the fermented stevia infusion of the invention may be used as a ‘sugar-free’ sweetening ingredient.


In some embodiments, the pH of the infusion at the start of the fermentation may be less than about 7. In some embodiments, the pH of the infusion at the start of the fermentation may be less than about 6.5. In some embodiments, the pH of the infusion at the start of the fermentation may be less than about 6. In some embodiments, the pH of the infusion at the start of the fermentation may be less than about 5.5.


In some embodiments, the pH of the infusion at the start of the fermentation may be more than about 4. In some embodiments, the pH of the infusion at the start of the fermentation may be more than about 4.5. In some embodiments, the pH of the infusion at the start of the fermentation may be more than about 5.


In some embodiments, the pH of the infusion at the start of the fermentation may be between about 5 and about 7. In some embodiments, the pH of the infusion at the start of the fermentation may be between about 5 and about 6.5. In some embodiments, the pH of the infusion at the start of the fermentation may be between about 5 and about 6.


In some embodiments, the pH of the infusion at the end of the fermentation may be more than about 2.5. In some embodiments, the pH of the infusion at the end of the fermentation may be more than about 3. In some embodiments, the pH of the infusion at the end of the fermentation may be more than about 3.1. In some embodiments, the pH of the infusion at the end of the fermentation may be more than about 3.5. In some embodiments, the pH of the infusion at the end of the fermentation may be more than about 4. In some embodiments, the pH of the infusion at the end of the fermentation may be more than about 4.5.


In some embodiments, the pH of the infusion at the end of the fermentation may be less than about 5.


In some embodiments, the pH of the infusion at the end of the fermentation may be less than about 4.5. In some embodiments, the pH of the infusion at the end of the fermentation may be less than about 4. In some embodiments, the pH of the infusion at the end of the fermentation may be less than about 3.9. In some embodiments, the pH of the infusion at the end of the fermentation may be less than about 3.8. In some embodiments, the pH of the infusion at the end of the fermentation may be less than about 3.5.


In some embodiments, the pH of the infusion at the end of the fermentation may be between about 2.5 and about 4.5. In some embodiments, the pH of the infusion at the end of the fermentation may be between about 3 and about 4.5. In some embodiments, the pH of the infusion at the end of the fermentation may be between about 3 and about 4. In some embodiments, the pH of the infusion at the end of the fermentation may be between about 3.1 and about 3.9. In some embodiments, the pH of the infusion at the end of the fermentation may be between about 3.1 and about 3.8.


Without wishing to be bound by theory, it is thought that an observed reduction in optical density during the fermentation process is also indicative of the biotransformation process. Optical density of the infusion may be measured and monitored with a UV-vis spectrophotometer, using methods known in the art. For example, in some embodiments a cell density meter such as the UltrospecTM 10 Classic (supplied by Biochrom) may be used.


In some embodiments, the optical density measured at a wavelength of 600 nm (OD600) of the infusion at the end of the fermentation may be less than about 1. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be less than about 0.9. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be less than about 0.8. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be less than about 0.7. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be less than about 0.6.


In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be more than about 0.1. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be more than about 0.12. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be more than about 0.15. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be more than about 0.2. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be more than about 0.25.


In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be in the range of about 0.1 to about 1. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be in the range of about 0.12 to about 0.9. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be in the range of about 0.15 to about 0.9. In some embodiments, the optical density (OD600) of the infusion at the end of the fermentation may be in the range of about 0.15 to about 0.8.


Without wishing to be bound by theory, in some embodiments the content of certain metabolites has been found to be indicative of a good sensory outcome in the final ingredient. In particular, in some embodiments the amounts of lactate and acetate in the infusion at the end of the fermentation may be optimised, to achieve a desired sensory outcome (e.g. a ‘clean’ tasting ingredient or beverage).


In some embodiments, the amount of lactate in the infusion at the end of the fermentation is less than about 15 g/L. In some embodiments, the amount of lactate in the infusion at the end of the fermentation is less than about 12 g/L. In some embodiments, the amount of lactate in the infusion at the end of the fermentation is less than about 10 g/L. In some embodiments, the amount of lactate in the infusion at the end of the fermentation is less than about 8 g/L.


In some embodiments, the amount of lactate in the infusion at the end of the fermentation is more than about 0.1 g/L. In some embodiments, the amount of lactate in the infusion at the end of the fermentation is more than about 0.2 g/L. In some embodiments, the amount of lactate in the infusion at the end of the fermentation is more than about 0.5 g/L. In some embodiments, the amount of lactate in the infusion at the end of the fermentation is less than about 1 g/L.


In some embodiments, the amount of lactate in the infusion at the end of the fermentation is from about 0 to about 12 g/L. In some embodiments, the amount of lactate in the infusion at the end of the fermentation is from about 0 to about 10 g/L. In some embodiments, the amount of lactate in the infusion at the end of the fermentation is from about 0.5 to about 10 g/L.


In some embodiments, the amount of acetate in the infusion at the end of the fermentation is less than about 4 g/L. In some embodiments, the amount of acetate in the infusion at the end of the fermentation is less than about 3 g/L. In some embodiments, the amount of acetate in the infusion at the end of the fermentation is less than about 2.5 g/L. In some embodiments, the amount of acetate in the infusion at the end of the fermentation is less than about 2 g/L.


In some embodiments, the amount of acetate in the infusion at the end of the fermentation is more than about 0.1 g/L. In some embodiments, the amount of acetate in the infusion at the end of the fermentation is more than about 0.2 g/L. In some embodiments, the amount of acetate in the infusion at the end of the fermentation is more than about 0.5 g/L..


In some embodiments, the amount of acetate in the infusion at the end of the fermentation is from about 0 to about 3 g/L. In some embodiments, the amount of acetate in the infusion at the end of the fermentation is from about 0 to about 2.5 g/L. In some embodiments, the amount of acetate in the infusion at the end of the fermentation is from about 0.2 to about 2.5 g/L.


Accordingly, a further aspect of the present invention is an ingredient, for example a sweetening ingredient, comprising steviol glycosides in aqueous solution and having physicochemical properties, for example a pH, optical density, lactate and acetate content, as described herein. The ingredient is obtainable using fermentation processes as described herein.


In some embodiments, the invention hence provides an ingredient, for example a sweetening ingredient, comprising steviol glycosides in aqueous solution, and having, for example:


a pH from about 3.1 to about 3.9;


an OD600 from about 0.15 to 0.8;


a lactate content from about 0 to about 10 g/L; and


an acetate content from about 0 to about 2.5 g/L.


Preferably the ingredient comprises at least 50 ppm total steviol glycosides. In some embodiments the ingredient comprises at least 100 ppm total steviol glycosides. In some embodiments the ingredient comprises at least 200 ppm total steviol glycosides. In some embodiments the ingredient comprises at least 500 ppm total steviol glycosides.


As noted above, in some embodiments the process optionally includes a step wherein the infusion is filtered before the fermentation microorganism is added, to remove the stevia plant material.


In some embodiments, the process optionally includes a step wherein the stevia infusion is sterilised or pasteurised (for example, by heating) to reduce the risk of contamination with other microorganisms, prior to addition of the fermentation microorganism.


In some embodiments, the process optionally includes one or more steps wherein additional liquid (e.g. water) is added to the infusion.


In some embodiments, after the fermentation step, some or all of the remaining solids, including e.g. biomass from the microorganism, may be removed or reduced, to leave a fermented infusion suitable for use as a sweetening ingredient. In some embodiments, the fermented infusion is filtered (or centrifuged, etc) to remove solids.


The resulting fermented infusion is ready to use as an ingredient, e.g. sweetening ingredient, in liquid form. In some embodiments, the final product may be pasteurised or sterilised before being packaged and/or used.


In some embodiments, the ingredient of the invention is pasteurised. In some embodiments, the process of the invention comprises a pasteurisation step. In some embodiments, pasteurisation comprises heating to a temperature of at least 70° C., at least 80° C., at least 90° C., or at least 95° C.


In some embodiments, the ingredient may be concentrated and/or dried before packaging and/or use. In some embodiments, an ingredient of the invention is dried to provide a solid ingredient. Drying may be performed by methods known in the art. In some embodiments, drying comprises, for example, evaporation, optionally at reduced pressure; freeze drying; spray drying. Depending on the carriers/auxiliaries the products may also be obtained by spray granulation; melt granulation; coacervation; coagulation; extrusion; melt extrusion; emulsion processes; coating or other suitable encapsulation processes and optionally a suitable combination of said processes


In some embodiments, the resulting solid ingredient may be formulated as a granulated or powdered product e.g. a granulated or powdered sweetener. In some embodiments, the solid ingredient may be formulated in a tablet e.g. a sweetener tablet.


The ingredients described herein may be used in the production of a food or beverage product. Accordingly, a further aspect of the present invention is the use of a sweetening ingredient, as described herein, in the production of a food or beverage product. A further aspect is a food or beverage product, preferably a reduced sugar, low-sugar or sugar-free beverage product, comprising a sweetening ingredient as described herein.


In some embodiments, the food or beverage product is a beverage including, without limitation, a squash, a cordial, a juice, an infusion, a carbonated beverage or another soft drink.


In some embodiments, advantageously, a sweetening ingredient of the invention may have less of a foaming effect than previously known stevia-based sweeteners, in particular solvent-extracted stevia preparations.


In some embodiments, the food or beverage product is a foodstuff including, without limitation, a confectionery item. In some embodiments, the foodstuff is a biscuit, cake, or other baked good. In some embodiments, the foodstuff is a sweet or chocolate product. In some embodiments, the foodstuff is a chewing gum. In some embodiments, the foodstuff is selected from condiments including, but not limited to, sauces, ketchups, dressings, or table sauces. In some embodiments, the foodstuff is a cereal product, for example a breakfast cereal, or a snack (e.g. from potato, maize, peanut). In some embodiments the foodstuff is an animal product, for example a milk product (including but not limited to dairy, ice cream, cheese etc.) or an egg product. In other embodiments, the foodstuff is a vegetable or fruit product (e.g. fruit preparations, vegetable products). In yet further embodiments, the foodstuff is selected from a soya product including, but not limited to, tofu, tempeh or soya milk. In some embodiments, the foodstuff may be a spice mixture or other seasoning.


In some embodiments, the sweetening ingredient is added to the food or beverage in an amount from about 0.2% (v/v), from about 0.5%, from about 1%, from about 1.5% or from about 2%. In some embodiments, the sweetening ingredient is added to the food or beverage in an amount up to about 2.5% (v/v), up to about 3%, up to about 4%, up to about 5% or up to about 10%. In some embodiments, the sweetening ingredient is added to the food or beverage in an amount of about 0.5% (v/v). In some embodiments, the sweetening ingredient is added to the food or beverage in an amount of about 1% (v/v). In some embodiments, the sweetening ingredient is added to the food or beverage in an amount of about 1.5% (v/v).


In some embodimenbts, the ingredient is added in an amount of about 0.01 mg/L, preferably more than about 0.1 mg/L, preferably more than about 1 mg/L, based on the total preparation. In further embodiments, the preparation comprises a total quantity in the range of 0.01 to 10 000 mg/L, 0.1 to 1000 mg/L, preferably 0.1 to 500 mg/L, particularly preferably 0.1 to 100 mg/L, of the ingredient, based on the total weight of the preparation.


In some embodiments, the sweetening ingredient is added to the food or beverage in an amount from about 0.2% (w/w), from about 0.5%, from about 1%, from about 1.5% or from about 2%. In some embodiments, the sweetening ingredient is added to the food or beverage in an amount up to about 2.5% (w/w), up to about 3%, up to about 4%, up to about 5% or up to about 10%. In some embodiments, the sweetening ingredient is added to the food or beverage in an amount of about 0.5% (w/w). In some embodiments, the sweetening ingredient is added to the food or beverage in an amount of about 1% (w/w). In some embodiments, the sweetening ingredient is added to the food or beverage in an amount of about 1.5% (w/w).


In some embodiments, the sweetening ingredient replaces the equivalent of about 2 g/L of sugar in the beverage or food product. In some embodiments, the sweetening ingredient replaces the equivalent of up to about 3 g/L of sugar in the beverage or food product. In some embodiments, the sweetening ingredient replaces the equivalent of up to about 4 g/L of sugar in the beverage or food product. In some embodiments, the sweetening ingredient replaces the equivalent of up to about 5 g/L of sugar in the beverage or food product. In some embodiments, the sweetening ingredient replaces the equivalent of up to about 10 g/L of sugar in the beverage or food product.


In some embodiments, the sweetening ingredient replaces the equivalent of about 2 g/kg of sugar in the beverage or food product. In some embodiments, the sweetening ingredient replaces the equivalent of up to about 3 g/kg of sugar in the beverage or food product. In some embodiments, the sweetening ingredient replaces the equivalent of up to about 4 g/kgL of sugar in the beverage or food product. In some embodiments, the sweetening ingredient replaces the equivalent of up to about 5 g/kg of sugar in the beverage or food product. In some embodiments, the sweetening ingredient replaces the equivalent of up to about 10 g/kg of sugar in the beverage or food product.


The features disclosed in the foregoing description, or in the following claims, or in the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for obtaining the disclosed results, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.


While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when given this disclosure. Accordingly, the exemplary embodiments of the invention set forth above are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the spirit and scope of the invention.


For the avoidance of any doubt, any theoretical explanations provided herein are provided for the purposes of improving the understanding of a reader. The inventors do not wish to be bound by any of these theoretical explanations.


Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.


Throughout this specification, including the claims which follow, unless the context requires otherwise, the word “comprise” and “include”, and variations such as “comprises”, “comprising”, and “including” will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.


It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent “about,” it will be understood that the particular value forms another embodiment. The term “about” in relation to a numerical value is optional and means for example +/−10%.


EXAMPLES

General Methods


1. Steviol Glycosides HPLC Analysis Method (Examples 2 to 6)

1. Introduction


The samples were analysed using a method adapted from the Jefca 2017 monograph Steviol Glycosides HPLC method. They were run on an Agilent HPLC 1100 system a gradient method was utilised with a Phenomenex Luna 5 μm C18(2), 100A, (250 mm×4.6 mm, 5 μm) column, the detector was set 210 nm. The steviol glycoside content was quantified by comparison with external standards.


2. Experimental


Reagents & Standards


Steviol glycoside standard solution Jefca mixture 0.2 mg/ml was obtained from Chromadex (part No 00010175) containing the following Steviosides: Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside F, Dulcoside A, Steviolbioside. HPLC grade deionised water and HPLC grade acetonitrile was obtained from VWR.


Mobile phase


Solvent A: Deionised Water


Solvent B: Acetonitrile


The HPLC Method employed was a gradient method the same as reported in Jefca.


HPLC Gradient Time table:



















%
%
Flow



Time
Solvent
Solvent
Rate



(min)
A
B
(mL/min)









 0
85
15
0.3



40
70
30
0.3



60
55
45
0.3



70
55
45
0.3



70.1
85
15
0.3



90
85
15
0.3










Standard Preparation


The standard solution was used as supplied by Chromadex.


Instrumentation and Conditions


An Agilent 1100 HPLC System including quaternary pump, a temperature controlled column compartment set at 50° C., an autosampler and VWD absorbance detector was used for the analysis. The detector was set at 210 nm. The data acquisition was done using WATER Empower 3 software. The column used for HPLC was a reversed phase Luna 5 μm C18(2), 100A, (250 mm x 4.6 mm, 5 μm) Phenomenex.


Analysis Procedure


For the RP-HPLC method the column was flushed 30ml mobile phase (85:15 deionised water: Acetonitrile). The samples were bracketed with standard at the beginning and the end of a run for accuracy of retention times. Sample injection volume 20 μl. A calibration curve was constructed using on-column dilution method taking different volumes of the Jefca standard mixture.



















Level 1
Level 2
Level 3
Level 4
Level 5




Injection
Injection
Injection
Injection
Injection




volume
volume
volume
volume
volume




(1 μl)
(5 μl)
(10 μl)
(15 μl)
(20 μl)





















Rebaudioside D
9.15
45.75
91.5
137.25
183
mg/l


Rebaudioside A
9.55
47.75
95.5
143.25
191
mg/l


Stevioside
9.3
46.5
93
139.5
186
mg/l


Rebaudioside F
9.45
47.25
94.5
141.75
189
mg/l


Rebaudioside C
9.25
46.25
92.5
138.75
185
mg/l


Dulcoside A
9.5
47.5
95
142.5
190
mg/l


Rubusoside
8.85
44.25
88.5
132.75
177
mg/l


Rebaudioside B
9
45
90
135
180
mg/l


Steviolbioside
9.25
46.25
92.5
138.75
185
mg/l









2. Volatiles Analysis HPLC Method


Extraction of volatiles by Headspace Solid Phase Micro Extraction (SPME) for GC/MS Analysis


An appropriate amount of sample was transferred to a 20 ml vial, which was then sealed. Vials were equilibrated at 75° C. for 5 minutes with agitation. The headspace of the vial was then sampled for 5 minutes at 75° C. with agitation using carboxen/polydimethylsiloxane /divinylbenzene coated SPME fibre. The volatiles adsorbed onto the fibre were analysed by thermal desorption at 270° C. in the injector port of the GC/MS.


GC/MS Analysis of Volatiles


Analysis was carried out an Agilent 7890A gas chromatograph (GC) and Agilent 7200 accurate mass Q-TOF mass spectrometer (MS) via CTC Combi-Pal autosampler.


GC/MS conditions were as follows:


Column : 30 mm x 0.25 mm fused silica with ZB-semivolatiles stationary phase


Helium carrier gas flow rate: 1 mL min−1


Injector temperature: 270° C.


Column temperature: 5 min at 40° C.; then 4° C. min−1 to 200° C.; then 30° C. min-1 to 350° C., hold for 3 minutes

    • MS analysis mode: Scam (33-350 m/z)


Peaks were tentatively identified by spectral matching with the MIST library of mass spectral data.


3. Sensory Testing—Exemplary Methodology


Sensory tests are performed using a Quantitative Descriptive Analysis (QDA). A QDA evaluates if there are differences between samples and what the differences are (qualitative=description element, and by how much the samples differ=quantitative element). This methodology is run with sensory panellists who are a group of consumers who have been screened for their sensory acuity and trained on their senses to articulate what they perceive when consuming a beverage. They have also been trained on a range of sensory methodologies. The measure obtained from a sensory panel is objective. A minimum of 6-7 panellists participate in the studies and results are taken in duplicate to ensure reproducibility.


The samples are presented first all at a time to the sensory trained panel who, during a round table discussion, initially agree on the sensory attributes or descriptors which best describe the products, in order to develop a sensory vocabulary. A sensory scientist moderates the discussion and collects the attributes selected by the panel which are clear for them, easily defined and describe differences between the samples under study.


Then sensory evaluation takes place in sensory booths where each panellist assesses the samples individually. The panellists rate one sample at a time in an undefined line scale from Low to High (0-100 of each attribute). The samples are presented in a randomised and balanced order to avoid first order and carry over effects. The data collection is done online via FIZZ (Sensory Software) and the data analysis carried out with FIZZ and XLSTAT. The outcome of the data analysis is a spider graph (see e.g. FIGS. 1 and 7). Statistical Significance testing in the form of ANOVA (Analysis of Variance) and an LSD test is performed. This determines on which attributes the samples are significantly different (if any). P-value is taken as <0.05 (using 95% confidence).


Example 1
General Protocol for Preparation of Fermented Stevia Infusion

Stevia leaf (dried) is added to water at the desired temperature. The leaves are allowed to steep at this temperature (brewing stage) for the required infusion time and the infusion is optionally then filtered to remove the spent leaves. Further (cold) water is added if needed, to dilute the infusion to a required volume and/or reduce its temperature. A carbohydrate feedstock (e.g. sugar) may be added to the infusion (e.g. during the steep, or at any point thereafter).


Alternatively, in some embodiments, a continuous column method to prepare the stevia infusion may be used (see FIG. 10).


The microorganism (e.g. the yeast) is prepared by suspending in water and pre-activation, if necessary (e.g. by addition of sugar).


The infusion is heated or cooled if needed, to an appropriate temperature for fermentation. The preparation of the microorganism is then added to the infusion, which is allowed to ferment.


Fermentation process is monitored analytically using methods which are known in the art.


Exemplary pH-meter, densimeter and refractometer used for basic analytics:


pH Meter: Mettler Toledo Seven Easy


Refractometer: Bellingham and Stanley RFM340+


Density Meter: Anton Paar DMA 4500M


Monitoring of fermentation progress can also be assessed, for example, using spectroscopic methods such as the Acetoscan' machine manufactured by CETOTEC GmbH.


The microorganism may be removed (e.g. by filtration) after the fermentation step is complete.


An exemplary filtration comprises a plate and frame filter with cellulose filter sheets (Beco KD3 200×200 filter sheets from Eaton filtration products; rated at 10microns). For a 600 litre ferment, typically 30 sheets would be used, getting 800-1000 g of yeast that can be scraped off. The pump supplying liquid pressurises to 30psi; typical expected loss of 15-20 litres of liquid during filtration.


The resultant product is optionally pasteurised (e.g. by heating)—see Example 3.


Example 2
Fermentation with S. Cerevisiae Yeast

Experimental parameters:
















Jar
Raw material,



#
supplier and dose g/L









A
Stevia (Mane) @1.2 g/L



B
Stevia (Mane) @5 g/L



C
Stevia (Mane) @10 g/L



























Infusion (step 1):





Hot water
1500
mL



Time (tea steep)
45
min



Temp (start)
70
° C.



Temp (end)
60
° C.



Fermentation (step 2):





Sugar (3Bx)
30
g/L



Yeast
2
g



Infusion (from step 1)
1500
mL



Cold Water
2500
mL



Water for Yeast
1000
mL










Stevie Infusion Preparation:


Sugar: 30 g/L total sugar per jar was used, to get around 3Bx for each jar. For 5 L of ferment this corresponds to 150 g of sugar. 100 g was added and dissolved in the infusion, with the leaves. Remaining part of the sugar, 50 g, was used for the yeast activation (below).


Yeast: A strain of S. cerevisiae yeast was used, at 0.4 g/L. A total of 2 g per jar was pre-activated for all jars. The yeast was activated separately, the total of 2 g were dissolved in 1 L of water with the remaining part of the sugar (50 g) and kept there for 105 min.


Before adding the yeast to the infusion, it was checked that the solution has a temperature inferior to 30° C. to be sure not to kill the yeast.


Water: The remaining part of the 5 L of water was added before addition of the activated yeast solution to quickly bring down the temperature below 30° C.


Results:


Monitoring of Fermentation Reaction:




















Jar
Start
Day 1
Day 2




#
(0 h)
(18 h)
(42 h)









Brix
A
3.27   
2.88   
2.49   




B
3.27   
2.68   
1.8    




C
3.34   
2.59   
1.52   



pH
A
5.57   
3.95   
3.52   




B
5.57   
3.97   
3.5    




C
5.57   
4.04   
3.58   



Density
A
1.01302
1.01075
1.00819



(SG)
B
1.01289
1.00944
1.00597




C
1.01299
1.00847
1.00399










Steviol Glycosides Analysis:














Steviol Glycosides HPLC analysis - unfermented













Jar #:
A d1
B d1
C d1








Reb D
3.7
17.4
32.6
mg/l



Reb A
88.6
320
541.5
mg/l



Stevioside
30
117
194.6
mg/l



Reb F
2.4
21
41.5
mg/l



Reb C
11.6
52.2
103
mg/l



Dulcoside A
nd
7.3
26.8
mg/l



Rubusoside
nd
4.7
12.7
mg/l



Reb B
nd
7.6
16.7
mg/l



Steviolbioside
nd
6.5
16.3
mg/l



Total steviol glycosides
136.4
553.8
985.7
mg/l











Steviol Glycosides HPLC analysis - fermented













Jar #:
A D3
B D3
C D3
Units







Reb D
3.9
15.1
28.1
mg/l



Reb A
90.4
309.4
572.9
mg/l



Stevioside
29.5
109.1
193
mg/l



Reb F
2.7
10.8
49.4
mg/l



Reb C
11.6
48.3
90.5
mg/l



Dulcoside A

3.9
8.8
mg/l



Rubusoside

4.5
9.5
mg/l



Reb B

5.1
10.1
mg/l



Steviolbioside

5
11
mg/l



Total steviol glycosides
138.1
511.2
973.3










Sensory Profile:


As shown in FIG. 1, a significant modification in the sensory profile of the stevia infusion is achieved by fermentation.


Volatiles Analysis:


Volatiles analysis performed using analytical HPLC showed the following changes in composition.


Decrease in Terpenoid Compounds After Fermentation:
















Compound
Descriptor









alpha-Pinene
fresh, sweet, pine, earthy



beta-Bourbonene
herbal, woody, floral, balsamic



alpha-Bergamotene
woody, warm, tea



Spathulenol
earthy, herbal, fruity










Increased After Fermentation:
















Compound
Descriptor









Ethanol
alcoholic



2-Methyl-1-propanol
ethereal, wine



3-Methylbutanal
alcoholic, fruity



2-Methylbutanol
alcoholic, fruity



3-Methylbutyric acid
sour, sweaty, cheesy



2-Methylbutyric acid
acidic, fruity, cheesy



3-Methylbutyl acetate
sweet, fruity, solvent



2-Methylbutyl acetate
fruity



Butoxyacetic acid




Benzaldehyde
almond



Ethyl hexanoate
fruity



Benzenacetaldehyde
green, sweet, floral



alpha-Dimethylstyrene
phenolic, plastic, clove



Benzeneethanol
floral



Octanoic acid
fatty, oily, cheesy



Ethyl octanoate
fruity



Nonanoic acid
fatty, cheesy, dairy



Decanoic acid
rancid, sour, fatty



beta-Damascenone
sweet, fruity, earthy, floral



9-Decenoic acid
green, fruity, fatty, soapy



Ethyl decanoate
sweet, waxy, fruity










Example 3
Fermentation with S. Cerevisiae Yeast; Addition of Pasteurisation Step

Experimental Parameters:
















Jar
Raw material,



#
supplier and dose g/L









A
Stevia (Natura) @1.2 g/L



B
Stevia (Natura) @5 g/L



C
Stevia (Natura) @10 g/L



























Infusion (step 1):





Hot water
1500
mL



Time (tea steep)
30
min



Temp (start)
65
° C.



Temp (end)
/
° C.



Fermentation (step 2):





Sugar (3Bx)
30
g/L



Yeast
2
g



Infusion (from step 1)
1500
mL



Cold Water
2500
mL



Water for Yeast
1000
mL










The stevia infusion was prepared and fermented (using a S. cerevisiae strain) using the same method as for Example 2.


Results:


Monitoring of fermentation reaction:




















Jar
Start
Day 1
Day 2




#
(0 h)
(18 h)
(42 h)









Brix
A
3.2    
2.85   
2.47   




B
3.22   
2.61   
2.02   




C
3.26   
2.49   
1.82   



pH
A
5.35   
4.1    
3.73   




B
5.21   
4.04   
3.66   




C
5.12   
4.06   
3.67   



Density
A
1.01089
1.00844
1.00639



(SG)
B
1.01063
1.00692
1.00395




C
1.0108 
1.00581
1.00181










Steviol alycosides analysis:












Steviol Glycosides HPLC analysis - fermented














A
B
C
Unit

















Reb D
5.5
22.2
37.3
mg/l



Reb A
36.1
392.2
673.7
mg/l



Stevioside
108.0
132.6
231.8
mg/l



Reb F
3.8
11.3
22.6
mg/l



Reb C
14.8
52.6
92.8
mg/l



Dulcoside A

3.9
6.7
mg/l



Rubusoside
3.4
8.3
16.2
mg/l



Reb B

6.5
11.9
mg/l



Steviolbioside

7.9
13.3
mg/l



Total steviol glycosides
171.6
637.5
1106.3
mg/l










Pasteurisation step:


The fermented infusion was pasteurised by heating using a water bath, with temperatures taken manually using a thermometer and recorded to give a pasteurisation curve as shown in the table below:

















Time
Display (° C.)
Bottle (° C.)









02:32
46.3
41.8



02:38
52
46.8



 3.02
73.2
68.9



 3.04
74.9
70.1



 3.05
75.3
70.9



 3.06
76.4
71.8



 3.07
77
72.6



 3.08
76.7
73.3



OFF
76
73.7










Pasteurisation may also be carried out using a Miele Pasteur and a datalogger with a probe that automatically measures the temperature.


Example 4
Fermentation with S. Cerevisiae Yeasts; Comparison with Other Plant Ingredients

Experimental parameters:














Jar #
Raw material, supplier and dose g/L
Yeast strain







C
Stevia (Natura SAS) @ 10 g/L
i


E
Stevia (Natura SAS) @ 10 g/L
ii


F
Stevia (Natura SAS) @ 30 g/L
i


G
Monk Fruit Concentrate (MFC) @ 2 g/L
i


H
Stevia (Natura) @5g/L + MFC @ 1 g/L
i


I
Stevia (Layn WS1905002) @ 10 g/L
i


J
Stevia (Layn WS1905005) @ 10 g/L
ii


K
Stevia (M-B) @ 10 g/L
ii


L
Chinese Blackberry leaves (Layn)
ii



@ 10 g/L



M
Chinese Blackberry leaves (M-B) @ 10 g/L
ii
























Infusion (step 1):






















Hot water
1400
mL



Time (tea steep)
30
min



Temp (start)
65
° C.



Temp (end)
/
° C.



Fermentation (step 2):





Sugar (3Bx)
30
g/L



Yeast
1.2
g



Infusion (from step 1)
1000
mL



Cold Water
1400
mL



Water for Yeast
600
mL










The infusion was prepared and fermented (using S. cerevisiae yeast strains) using a method as described for Example 2.


Results:


Monitoring of fermentation reactions:

















Jar #
Start (0 h)
Day 1 (18 h)
Day 2 (42 h)







Brix
C
2.92
2.33
1.16



E
3.08
2.29
1.79



F
3.05
1.59
1.27



G
4.19
3.92
3.54



H
3.2
2.31
1.74



I
2.44
1.19
0.62



J
3.07
2.57
2.2



K
3.4
2.49
1.76



L
3.11
2.67
2.26



M
3.16
2.68
2.27


PH
C
4.9
3.96
3.63



E
5.48
4.2
3.89



F
4.88
4.15
4



G
5.2
3.98
3.57



H
4.96
3.88
3.57



I
5.23
4.14
3.92



J
5.65
4.51
4.33



K
5.85
4.24
3.98



L
5.7
4.58
4.41



M
5.54
4.45
4.27


Density (SG)
C
1.01038
1.00509
1.00128



E
1.01006
1.00528
1.0018



F
1.01095
1.00281
1.00101



G
1.01486
1.01286
1.01066



H
1.01138
1.00717
1.00361



I
1.00733
1.00221
0.9988



J
1.01026
1.00739
1.00483



K
1.0114
1.00573
1.0002



L
1.01045
1.00764
1.00525



M
1.01053
1.00751
1.00538









Steviol glycosides analysis:




















C
E
F
I
J
K
Unit







1st analysis









Reb D
35.1
52.9
18.3
36.5
nd
3.6
mg/l


Reb A
684.3
642.7
1515.5
357.2
nd
366.0
mg/l


Stevioside
235.1
220.2
545.1
263.3
nd
258.7
mg/l


Reb F
21.6
20.4
58.5
13.3
nd
13.3
mg/l


RebC
90.1
84.2
210.4
58.0
nd
55.3
mg/l


Dulcoside A
5.8
5.8
15.0
7.6
nd
8.5
mg/l


Rubusoside
6.8
6.0
12.1
4.5
183.2
10.6
mg/l


Reb B
11.4
11.3
28.0
6.9
nd
4.5
mg/l


Steviolbioside
13.6
12.9
32.1
10.1
nd
7.0
mg/l


Total Steviol
1103.6
1056.4
2435.1
757.5
183.2
727.5
mg/l


Glycosides









2nd analysis









Reb D
33.3
31.9
84.7
18.5
24.4
21.7
mg/l


Reb A
661.1
621.2
1465.8
351.8
nd
362.9
mg/l


Stevioside
230.1
215.0
542.8
259.6
nd
261.2
mg/l


Reb F
24.1
20.1
53.1
15.9
nd
3.8
mg/l


RebC
92.9
85.1
217.0
61.2
nd
2.9
mg/l


Dulcoside A
7.5
6.9
17.6
9.1
nd
8.8
mg/l


Rubusoside
13.3
16.9
32.9
18.6
174.7
22.9
mg/l


Reb B
12.2
11.7
30.7
7.3
nd
6.1
mg/l


Steviolbioside
15.7
14.9
35.3
11.7
5.5
8.7
mg/l


Total Steviol
1090.2
1023.6
2480.0
753.7
204.6
699.0
mg/l


Glycosides









Example 5
Optimisation of Infusion Step

Experimental parameters:
















Jar #
Raw material, supplier and dose g/L









90/60
Stevia (Natura Greece) @ 90 g/L



90/30
Stevia (Natura Greece) @ 90 g/L



30/60
Stevia (Natura Greece) @ 30 g/L



30/30
Stevia (Natura Greece) @ 30 g/L



30 1/3
Stevia (Natura Greece) @ 30 g/L



30 1/2
Stevia (Natura Greece) @ 30 g/L



90 1/2
Stevia (Natura Greece) @ 90 g/L

























Infusion:











Hot water
variable
mL



Time (tea steep)
variable
min



Temp (start)
60
° C.



Temp (end)
/
° C.










Stevia infusion preparation:


Seven different stevia infusions were prepared (but were not fermented in this trial); 1.5 L of total infusion in each jar:


90/60-90 g/L, infused at 60° C., using all the water topping up only the amount use by the leaves and kept for 60 min. 90/30-90 g/L, infused at 60° C., using all the water topping up only the amount use by the leaves and kept for 30 min. 30/60-30 g/L, infused at 60° C., using all the water topping up only the amount use by the leaves and kept for 60 min. 30/30-30 g/L, infused at 60° C., using all the water topping up only the amount use by the leaves and kept for 30 min. 90 1/2-90 g/L, infused at 60° C., using half of the water amount and topping up the rest and kept for 60 min. 30 1/2-30 g/L, infused at 60° C., using half of the water amount and topping up the rest and kept for 60 min. 30 1/3-30 g/L, infused at 60° C., using a third of the water amount and topping up the rest and kept for 60 min.


Results:


Steviol glycosides analysis:


Full analysis is shown in Table 5.









TABLE 5







HPLC analysis of steviol glycosides in Example 5
































Total













Dulco-



Steviol
Steviol









Stevio-
Reb
Reb
side
Rub-
Reb
Steviol-
Glyco-
Equiv-


Comment



Jar#
Reb D
Reb A
side
F
C
A
usoside
B
bioside
sides
alents

Bx
on taste
Smell





30 1/3
 51.7
986.5
 615  
 41.8
219.2
17.4
nd
 6.9
14.7
1953.2
 692.4
mg/l
/




30 1/2
 56.4
1142  
 715.6
 49.3
255.5
22.3
nd
 7.3
11  
2259.3
 800.4
mg/l
1.15
profile similar
slightly
















sweetness to
herbal but
















30/30 slightly
not so
















less lingering
strong
















than 30/30

















slightly

















less intensity

















than 90/30



90 1/2
128.8
1813.6
1129.8
 82.4
413  
39  
10.1
14.2
22.1
3653  
1293.6
mg/l
1.81
watery not
no smell
















enough

















sweet even if

















less lingering



30/30
 65.4
1315.2
 835.8
 57  
293.3
27.7
nd
 8.4
12.7
2615.6
 927.2
mg/l
1.31
same profile
herbal but


1L













of the 90/30
the usual
















but slightly
smell of
















less intense
stevia

















infusion


30/60
 63.2
1294.3
 820.7
 54.9
288.1
25.5
nd
 7.5
15.2
2569.4
 911.1
mg/l
1.32
cooked, lot
cooked


1L













of aftertaste
smell, not
















but same
much
















sweetness
herbal
















of 90/30



90/30
251.1
3125.3
1982.2
134.9
725.2
61.1
12.8
24.6
40.6
6357.8
2250.4
mg/l
3.32
sweeter and
strong


1L













herbal
herbal
















aftertaste



90/60
236.5
2995.5
1893.9
131.3
697.2
64.1
16.8
29.2
48.2
6112.7
2166.2
mg/l
3.19
less aftertaste
herbal but


1L













but quite less
in the
















sweetness
norm









Example 6
Fermentation of Stevia Infusions with S. Cerevisiae Yeast

Experimental parameters:
















Jar #
Raw material, supplier and dose g/L









SNSA30R
Stevia Natura SAS @ 30 g/L



P30
Stevia Paraguay @ 30 g/L



P60
Stevia Paraguay @ 60 g/L



























Infusion (step 1):









Hot water
2500
mL



Time (tea steep)
30
min



Temp (start)
60
° C.



Temp (end)
/
° C.







Fermentation (step 2):









Sugar (3Bx)
30
g/L



Yeast
1.2
g



Infusion (from step 1)
2500
mL



Cold Water
0
mL



Water for Yeast
500
mL










The stevia infusion was prepared and fermented (using a S. cerevisiae strain) using the method as described for Example 2.


Results:


Monitoring of fermentation reaction:
















Jar #
Start (0 h)
Day 1 (18 h)







Brix
SNSA30R
4.09
2.77



P30
3.85
2.5



P60
3.01
1.71


PH
SNSA30R
5.67
4.4



P30
5.64
4.48



P60
5.69
4.89


Density (SG)
SNSA30R
1.01426
1.00792



P30
1.01488
1.00749



P60
1.00851
1.00427









Steviol glycosides analysis:























Reb D
Reb A
Stevioside
Reb F
RebC
Dulcoside A
Rubusoside
Reb B
Steviolbioside
Total

























SNSA
107.286
1576.87
596.048
36.272
184.126
0.032

19.83
25.767
2546.233


30 R












P30
47.242
990.778
740.306
24.109
130.667
0.219

17.454
20.916
1971.691


P60
57.925
1706.62
1301.776
48.361
243.38
8.465
3.283
45.406
48.24
3463.452


SNSA
87.991
1580.95
603.807
38.521
189.161
1.43

20.571
28.159
2550.587


30 R












18H*












P30
26.299
989.337
741.89
25.601
133.538
1.148
3.029
19.234
24.644
1964.72


18H*












P60
64.298
1723.04
1318.447
49.597
246.173
5.88
11.606
42.213
46.62
3507.874


18H*





*after 18H fermentation






Example 7
Screening of Fermentation Microorganisms

Small samples (15 ml) of a 30 g/L stevia infusion, prepared as described herein, were supplemented with 30-50 g/L glucose and then inoculated with various fermentation microorganisms (see Table 7-1 below) and incubated in 100 ml shake flasks at 28° C. with shaking. Microorganism biomass was freshly generated on a small scale to serve as inoculum in the infusion. Duration of fermentation was 48 hours, with the aim of completely consuming the sugar. Harvested samples were centrifuged in 15 ml or 50 ml PP tubes (e.g. Falcon, Corning) at room temperature for 10 minutes (e.g. at 4500 rpm in a Thermo Scientific Multifuge X3R). The supernatant was transferred to fresh PP tubes and pasteurized in a 75° C. waterbath (e.g. SW22, Julabo) for 20 min. The experiments were repeated twice.


Fermented samples were diluted 1:10 with mineral water. A panel of tasters ranked them on a liking scale. The most successful fermentations (i.e. those providing the most liked taste results) were repeated on a larger scale (500mL) to validate the results and provide samples for HPLC analysis (Table 7-2).


HPLC method I: HPLC analysis was performed using a Phenomenex Synergi column: 2.5 μm Hydro-RP 100 A, 100*2; Solvent A: 0.04% acetic acid; Solvent B: methanol +0.04% acetic acid; Flow: isocratic 50%B with 0.25 ml/min. Total runtime was 30 min. MS detection in negative mode 500-1200 m/z; MS fragmentation in negative mode Bruker AmazonSL lonTrap (auto or manual); Samples are diluted 1:10 in mobile phase and filtrated (hPTFE 0,22 μm) prior to injection; Injection volume: 10 μl.


Spectra and fragmentation patterns were compared against standards for Reb A, Reb D and Reb I. Retention times for these reference compounds were 21 min (m/z 965.47), 8.4 min (m/z 1127.71) and 20 min (m/z 1127.69), respectively.


Exemplary HPLC spectra for fermented samples according to the invention are shown in FIGS. 2 to 6.


Sensory results (trained panel):


Sensory profiles for exemplary fermented samples are shown in FIG. 7.


Reference sample (non fermented): green appearance (the darkest), ash/woody notes (aroma and flavour), no fermented notes (aroma and flavour).


Sample 10 (Zygosaccharomyces rouxii): very light in colour, mild ash/woody notes (aroma), fermented notes (aroma). The flavour is not very woody and has mild fermented notes, astringent mouthfeel.


Sample 19 (Meyerozyma guilliermondii): light colour, ash/woody and fermented aroma notes, fermented (the most) and woody flavour, astringent mouthfeel.









TABLE 7-1







screening












Residual





Sample
glucose g/L
Type of

Strain












#
Run 1
Run 2
sample
Microorganism
#





REF
50
50
control-no







microbial







inoculum




01
10
 7.75
fermented

Kluyveromyces lactis

A


02
 2
 0.50
fermented

Kluyveromyces lactis

B


03
 0
 0
fermented

Kluyveromyces marxianus

C


04
 2
 6.70
fermented

Kluyveromyces marxianus

D


05
 0
 0
fermented

Kluyveromyces marxianus

E


06
 0
30.00
fermented

Zygosaccharomaces rouxii

F


07
12
11.50
fermented

Pichia membranifaciens

G


08
 0
 0
fermented

Kluyveromyces marxianus

H


09
 0
 0
fermented

Kluyveromyces marxianus

J


10
 0
 3.00
fermented

Zygosaccharomyces rouxii

K


11
 0
 0
fermented

Kluyveromyces marxianus

L


12
 0
25.00
fermented

Kluyveromyces marxianus

M


13
 0
 0
fermented

Kluyveromyces marxianus

N


14
12
13.50
fermented

Kluyveromyces marxianus

P


15
 0
 0
fermented

Cyberlindnera jadinii

Q


16
 0
 8.50
fermented

Meyerozyma guilliermondii

R


17
 6
 0
fermented

Meyerozyma guilliermondii

S


18
 0
 0
fermented

Meyerozyma guilliermondii

T


19
 3
 0
fermented

Meyerozyma guilliermondii

U
















TABLE 7-2







scale-up












Residual






glucose
Type

Strain


Sample #
g/L
of sample
Microorganism
#





REF
50
control-no






microbial






inoculum




01_02
30.00
fermented

Zygosaccharomaces rouxii

F


03_04
 7.7
fermented

Pichia membranifaciens

G


05_06
 0.44
fermented

Zygosaccharomyces rouxii

K


07_08
 0.00
fermented

Cyberlindnera jadinii

Q


09_10
 5.00
fermented

Meyerozyma guilliermondii

U









Example 7B
Quantification of Steviol Glycosides of an Exemplary Sample

A stevia infusion (30 g/L) volume of 15m1, supplemented with 30 g/L glucose, was inoculated with strain # K (freshly generated biomass) and incubated in 100mIshake flasks at 28° C. with shaking (sample # S015B). Duration of fermentation was 48 hours, with the aim of completely consuming the sugar. Harvesting was done as in example 7A. Sample and control were analysed targeting a larger set of standards (qualitative analysis, FIG. 8) and quantitative assessment was performed (Table 7-3).


HPLC method II: HPLC analysis was performed using a Kinetex C18 2.6 μm 150*2,1 mm column; Solvent A: 0.1% formic acid Solvent B: AcN +0.1% formic acid; Flow: binary gradient 0.2 ml/min starting with 20%B.


Total runtime was 54 min. MS detection in negative mode 300-1300 m/z. Samples are diluted 1:10 in mobile phase (80%A/20%B) and filtrated (hPTFE 0,22 μm) prior to injection; Injection volume: 10p1


Spectra and fragmentation patterns were compared against standards for Reb E, Reb D, Reb M, Reb I, Reb A, Reb F, Reb C, Reb B as well as Stevioside, Dulcoside A, Rubusoside, Steviobioside.


HPLC spectrum for fermented sample # S015B is shown in FIG. 8.


Analytical results:









TABLE 7-3







Exemplary Steviol glycosides [ppm] analysis sample #S015B*


























Stevio-



Dulco-


Rubu-
Stevio-




RebA
RebB
RebC
RebD
side
RebF
RebM
RebN
sideA
RebI
RebG
sosice
bioside
RebE
























fermented
2434.7
238.3
236.6
3.0
498.1
53.9
32.7
32.2
11.2
1.7
0.0
271.9
33.1
0.2


(sample
















#S015B)
















unfermented
3066.4
356.5
312.6
107.7
1156.8
72.0
40.4
40.3
14.3
12.4
76.4
13.1
105.2
19.2





*Methodology: Food and Chemical Toxicology 41 (2003) 359-374






Example 8
Screening of Fermentation Microorganisms

Small samples (15 ml) of a 60 g/L stevia infusion, prepared as described herein, were supplemented with 30 g/L glucose and then inoculated with various fermentation microorganisms and incubated in 100 ml shake flasks. Microbial strains were cultivated on a small scale in shake flasks, harvested after 2 days, suspended in spent medium and subsequently served as inoculum in the infusion. Duration of fermentation step was 48 hours. Harvesting was done as in example 7A.


Experimental parameters:

















Medium














Strain
30 ml Medium,

resuspend in


















Culture
Species
Strain
300 ml shakeflask
Sugar g/L
spent medium
Temp
rpm
Gas



















MA.A1

Pichia

S-I
YPD
Glucose
15
2
28° C.
180
aerobic




membranifaciens











MA.A2

Cyberlindnera

S-II
YPD
Glucose
15
2
28° C.
180
aerobic




jadinii











MA.A3

Meyerozyma

S-III
YPD
Glucose
15
2
28° C.
180
aerobic




guilliermondii











MA.B1

Lactobacillus

S-IV
MRS
Glucose
20
2
37° C.
0
anaerobic




acidophilus











MA.B2

Lactobacillus

S-IV
MRS
Glucose
20
2
37° C.
0
anaerobic




acidophilus











MA.B3

Lactobacillus

S-IV
MRS
Glucose
20
2
37° C.
0
anaerobic




acidophilus











MA.C1

Lactobacillus

S-V
MRS
Glucose
20
2
37° C.
0
anaerobic




delbrueckil











MA.C2

Lactobacillus

S-V
MRS
Glucose
20
2
37° C.
0
anaerobic




delbrueckil











MA.C3

Lactobacillus

S-V
MRS
Glucose
20
2
37° C.
0
anaerobic




delbrueckil











MA.D1

Lactobacillus

S-VI
MRS
Glucose
20
2
28° C.
180
aerobic




fructivorans











MA.D2

Lactobacillus

S-VI
MRS
Glucose
20
2
28° C.
180
aerobic




fructivorans











MA.D3

Lactobacillus

S-VI
MRS
Glucose
20
2
28° C.
180
aerobic




fructivorans











MA.E1

Lactobacillus

S-VII
MRS
Glucose
20
2
28° C.
180
aerobic




sakei











MA.E2

Lactobacillus

S-VII
MRS
Glucose
20
2
28° C.
180
aerobic




sakei











MA.F1

Lactococcus

S-VIII
MRS
Glucose
20
2
28° C.
180
aerobic




raffinolactis











MA.F2

Lactococcus

S-VIII
MRS
Glucose
20
2
28° C.
180
aerobic




raffinolactis





















Infusion
Biomass




















Bacterium
Yeast
Stevia


Suspension (μl)
Temp




















Sample
Name
Strain
Name
Strain
(g/L)
sugar [g/L]
Bacterium
Yeast
[° C.]
rpm
Gas






















MA1

Lactobacillus

S-IV


60
Lactose
30
2000
0
37
40
anaerobic




acidophilus














MA2

Lactobacillus

S-V


60
Lactose
30
2000
0
37
40
anaerobic




delbrueckii














MA3

Lactobacillus

S-VI

Pichia

S-I
60
Glucose
30
1000
200
28
180
aerobic




fructivorars



membranifaciens












MA4

Lactobacillus

S-VI

Pichia

S-I
60
Glucose
30
1000
50
28
180
aerobic




fructivorars



membranifaciens












MA5

Lactobacillus

S-IV

Cyberlindnera

S-II
60
Glucose
30
1000
200
37
40
anaerobic




acidophilus



jadinii












MA6

Lactobacillus

S-V

Cyberlindnera

S-II
60
Glucose
30
1000
200
37
40
anaerobic




delbrueckii



jadinii












MA7

Lactobacillus

S-IV

Meyerozyma

S-III
60
Glucose
30
1000
200
37
40
anaerobic




acidophilus



guilliermondii












MA8

Lactobacillus

S-V

Meyerozyma

S-III
60
Glucose
30
1000
200
37
40
anaerobic




delbrueckii



guilliermondii












MA9

Lactobacillus

S-VI

Meyerozyma

S-III
60
Glucose
30
1000
200
28
180
aerobic




fructivorars



guilliermondii












MA10

Lactobacillus

S-VII

Meyerozyma

S-III
60
Glucose
30
1000
200
28
180
aerobic




sakei



guilliermondii












MA11

Lactococcus

S-VIII

Meyerozyma

S-III
60
Glucose
30
1000
200
28
180
aerobic




raffinolactis



guilliermondii










Analytical results:


HPLC method I: Sugar, acid analytics

    • Column: Rezex™ ROA-Organic Acid H+(8%), 300×4.6 mm
    • Solvent A: 0.1% (v/v) trifluoroacetic acid (TFA)
    • Flow: isocratic
    • Total runtime: 30 min
    • Detection by DAD (210 nm) and RID
    • Samples are diluted 2- or 5-fold (depending on expected metabolite concentrations) with appropriate volumes of 2% (v/v) and water to a final concentration of 1% (v/v) TFA and filtered (hPTFE 0.22 μm) prior to injection
    • Injection volume: 10 μl
    • Target analytes: acetic acid, formic acid, fructose, glucose, glycerol, lactic acid and succinic acid


















Glucose
Lactose
Glycerol
Lactate



Sample #
[g/L]
[g/L]
[g/L]
[g/L]
PH




















MA1
0.00
11.02
3.84
6.22
3.55


MA2
0.00
12.29
4.47
7.20
3.43


MA3
0.01
0.00
2.90
2.59
3.79


MA4
1.14
0.00
2.67
2.33
3.71


MA5
0.15
0.00
3.76
5.41
3.52


MA6
0.00
0.00
3.44
5.22
3.55


MA7
12.18
0.00
4.08
6.76
3.43


MA8
12.27
0.00
4.06
6.67
3.44


MA9
0.00
0.00
2.16
3.65
3.75


MA10
0.00
0.00
2.72
3.95
3.7


MA11
0.00
0.00
0.00
0.00
6.23


MA12
15.35
0.00
2.10
2.39
4.08









HPLC method II: Qualitative Steviolglycoside analytics

    • Column: Kinetex C18 2.6 μm 150*2.1 mm
    • Solvent A: 0.1% formic acid
    • Solvent B: AcN+0,1% formic acid
    • Flow: binary gradient 0.2 ml/min starting with 20%B
    • Total runtime: 54 min
    • MS detection in negative mode 300-1300 m/z
    • Samples are diluted 1:10 in mobile phase (80%A/20%B) and filtrated (hPTFE 0,22 μm) prior to injection
    • Injection volume: 10 μl
    • Analyte target: Reb E, D, M, I, A, F, C, B as well as Stevioside, Dulcoside A, Rubusoside, Steviobioside























MA3
MA4
















RT
CTLMA Glucose


delta


delta
















Analyte
[min]
Chromatogram
Area
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
118840896
173911168
55070272
46.34
182571200
63730304
53.63


RebD
15.9
EIC 1127.91 -All MS
216863408
291269824
74406416
34.31
323678240
106814832
49.25


RebM
17.8
EIC 1290.01 -All MS
25496538
37165300
11668762
45.77
42052952
16556414
64.94


RebI
26.2
EIC 1127.91 -All MS
5055771
3530707
−1525064
−30.16
6747964
1692193
33.47


RebA
26.9
EIC 965.77 -All MS
2403748096
2433838592
30090496
1.25
2511722496
107974400
4.49


Stevioside
27.3
EIC 849.63 -All MS
3471461120
3385091584
−86369536
−2.49
3575515136
104054016
3.00


RebF
29.4
EIC 935.72 -All MS
705598592
881053760
175455168
24.87
943990144
238391552
33.79


RebC
30.5
EIC 949.75 -All MS
2788458496
3132422912
343964416
12.34
3232423168
443964672
15.92


Dulcoside A
31
EIC 833.62 -All MS
165847904
218647424
52799520
31.84
243414560
77566656
46.77


Rubusoside
32.1
EIC 687.51 -All MS
305767872
283074944
−22692928
−7.42
290426112
−15341760
−5.02


RebB
35.9
EIC 803.65 -All MS
458243680
516187168
57943488
12.64
585368320
127124640
27.74


Steviolbioside
36.2
EIC 641.49 -All MS
338164416
371549696
33385280
9.87
395571360
57406944
16.98



















MA5
MA6
















RT
CTLMA Glucose


delta


delta
















Analyte
[min]
Chromatogram
Area
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
118840896
130134032
11293136
9.50
137113936
18273040
15.38


RebD
15.9
EIC 1127.91 -All MS
216863408
254554672
37691264
17.38
234558512
17695104
8.16


RebM
17.8
EIC 1290.01 -All MS
25496538
7768806
−17727732
−69.53
24318018
−1178520
−4.62


RebI
26.2
EIC 1127.91 -All MS
5055771
13411601
8355830
165.27
17822552
12766781
252.52


RebA
26.9
EIC 965.77 -All MS
2403748096
2429087488
25339392
1.05
2357415680
−46332416
−1.93


Stevioside
27.3
EIC 849.63 -All MS
3471461120
3350584064
−120877056
−3.48
3263184384
−208276736
−6.00


RebF
29.4
EIC 935.72 -All MS
705598592
757235776
51637184
7.32
697186496
−8412096
−1.19


RebC
30.5
EIC 949.75 -All MS
2788458496
2968667136
180208640
6.46
2819449344
30990848
1.11


Dulcoside A
31
EIC 833.62 -All MS
165847904
188527200
22679296
13.67
189754176
23906272
14.41


Rubusoside
32.1
EIC 687.51 -All MS
305767872
344994528
39226656
12.83
322388512
16620640
5.44


RebB
35.9
EIC 803.65 -All MS
458243680
499351200
41107520
8.97
450058240
−8185440
−1.79


Steviolbioside
36.2
EIC 641.49 -All MS
338164416
341210784
3046368
0.90
333605696
−4558720
−1.35



















MA7
MA8
















RT
CTLMA Glucose


delta


delta
















Analyte
[min]
Chromatogram
Area
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
118840896
105447792
−13393104
−11.27
111568408
−7272488
−6.12


RebD
15.9
EIC 1127.91 -All MS
216863408
187994496
−28868912
−13.31
201641680
−15221728
−7.02


RebM
17.8
EIC 1290.01 -All MS
25496538
29389772
3893234
15.27
32791622
7295084
28.61


RebI
26.2
EIC 1127.91 -All MS
5055771
8223428
3167657
62.65
2684789
−2370982
−46.90


RebA
26.9
EIC 965.77 -All MS
2403748096
2338661632
−65086464
−2.71
2344601600
−59146496
−2.46


Stevioside
27.3
EIC 849.63 -All MS
3471461120
3098226688
−373234432
−10.75
3175481600
−295979520
−8.53


RebF
29.4
EIC 935.72 -All MS
705598592
634420544
−71178048
−10.09
652564928
−53033664
−7.52


RebC
30.5
EIC 949.75 -All MS
2788458496
2672513280
−115945216
−4.16
2773452800
−15005696
−0.54


Dulcoside A
31
EIC 833.62 -All MS
165847904
157357360
−8490544
−5.12
191119392
25271488
15.24


Rubusoside
32.1
EIC 687.51 -All MS
305767872
395492736
89724864
29.34
445701824
139933952
45.76


RebB
35.9
EIC 803.65 -All MS
458243680
433592320
−24651360
−5.38
438780480
−19463200
−4.25


Steviolbioside
36.2
EIC 641.49 -All MS
338164416
280241536
−57922880
−17.13
313730464
−24433952
−7.23



















MA9
MA10
















RT
CTLMA Glucose


delta


delta
















Analyte
[min]
Chromatogram
Area
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
118840896
152601872
33760976
28.41
114700752
−4140144
−3.48


RebD
15.9
EIC 1127.91 -All MS
216863408
293296480
76433072
35.24
210775696
−6087712
−2.81


RebM
17.8
EIC 1290.01 -All MS
25496538
37296912
11800374
46.28
20888580
−4607958
−18.07


RebI
26.2
EIC 1127.91 -All MS
5055771
15741744
10685973
211.36
3196195
−1859576
−36.78


RebA
26.9
EIC 965.77 -All MS
2403748096
2582359808
178611712
7.43
2333189632
−70558464
−2.94


Stevioside
27.3
EIC 849.63 -All MS
3471461120
3521027072
49565952
1.43
3285468160
−185992960
−5.36


RebF
29.4
EIC 935.72 -All MS
705598592
903390464
197791872
28.03
686232064
−19366528
−2.74


RebC
30.5
EIC 949.75 -All MS
2788458496
3215042048
426583552
15.30
2708335360
−80123136
−2.87


Dulcoside A
31
EIC 833.62 -All MS
165847904
226486512
60638608
36.56
171326832
5478928
3.30


Rubusoside
32.1
EIC 687.51 -All MS
305767872
493957696
188189824
61.55
373185984
67418112
22.05


RebB
35.9
EIC 803.65 -All MS
458243680
561528000
103284320
22.54
433017664
−25226016
−5.50


Steviolbioside
36.2
EIC 641.49 -All MS
338164416
390759616
52595200
15.55
279482176
−58682240
−17.35



















MA11
MA1
















RT
CTLMA Glucose


delta


delta
















Analyte
[min]
Chromatogram
Area
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
118840896
138725744
19884848
16.73
180992656
−4367616
−2.36


RebD
15.9
EIC 1127.91 -All MS
216863408
244705056
27841648
12.84
309578080
4667808
1.53


RebM
17.8
EIC 1290.01 -All MS
25496538
40670944
15174406
59.52
39330088
−8121192
−17.11


RebI
26.2
EIC 1127.91 -All MS
5055771
4050426
−1005345
−19.89
13217289
8366603
172.48


RebA
26.9
EIC 965.77 -All MS
2403748096
2408734976
4986880
0.21
2476339200
45306368
1.86


Stevioside
27.3
EIC 849.63 -All MS
3471461120
3532585216
61124096
1.76
3459366656
−173717760
−4.78


RebF
29.4
EIC 935.72 -All MS
705598592
758464576
52865984
7.49
874148480
−2448256
−0.28


RebC
30.5
EIC 949.75 -All MS
2788458496
2929282560
140824064
5.05
3161312256
−261122048
−7.63


Dulcoside A
31
EIC 833.62 -All MS
165847904
233350144
67502240
40.70
206232352
−27650224
−11.82


Rubusoside
32.1
EIC 687.51 -All MS
305767872
593589312
287821440
94.13
366702304
3952288
1.09


RebB
35.9
EIC 803.65 -All MS
458243680
660848384
202604704
44.21
635858432
42884160
7.23


Steviolbioside
36.2
EIC 641.49 -All MS
338164416
529575456
191411040
56.60
426144640
52184800
13.95





















MA2



















RT
CTLMA Lactose


delta



















Analyte
[min]
Chromatogram
Area
Area
delta Area
Area %








RebE
14.3
EIC 965.77 -All MS
185360272
175762640
−9597632
−5.18





RebD
15.9
EIC 1127.91 -All MS
304910272
296507200
−8403072
−2.76





RebM
17.8
EIC 1290.01 -All MS
47451280
49408896
1957616
4.13





RebI
26.2
EIC 1127.91 -All MS
4850686
8732304
3881618
80.02





RebA
26.9
EIC 965.77 -All MS
2431032832
2474366976
43334144
1.78





Stevioside
27.3
EIC 849.63 -All MS
3633084416
3388836096
−244248320
−6.72





RebF
29.4
EIC 935.72 -All MS
876596736
850696576
−25900160
−2.95





RebC
30.5
EIC 949.75 -All MS
3422434304
3162701312
−259732992
−7.59





Dulcoside A
31
EIC 833.62 -All MS
233882576
193511808
−40370768
−17.26





Rubusoside
32.1
EIC 687.51 -All MS
362750016
294320576
−68429440
−18.86





RebB
35.9
EIC 803.65 -All MS
592974272
571269632
−21704640
−3.66





Steviolbioside
36.2
EIC 641.49 -All MS
373959840
365399744
−8560096
−2.29









Sensory results:


Fermented samples were applied in a beverage composition as follows:

    • Prepare a concentrated base of the drink that will be diluted 1:4 (1 part of base for 4 parts of water).
    • Add the ingredient at 10 g/L
    • Top up with the remaining part of water.
    • Blackcurrant drink:
    • BASE INGREDIENTS:
    • Water, Blackcurrant Juice from Concentrate (6%), Sugar, Thickener (Polydextrose), Acidity Regulator (Sodium Gluconate), Extracts of Carrot and Hibiscus, Vitamin C, Natural Blackcurrant Flavourings, Acid (Citric Acid).


Fermented samples were tasted by 4 trained tasters rating each descriptor from 1 to 5. A full sugar beverage was applied as positive benchmark (FS=Full sugar) and a beverage with artificial sweeteners served as negative control (H=Base with artificial sweeteners).























Sample Number
FS
H
21/1
21/2
21/5
21/6
21/7
21/8
21/9
21/10
21/11


























Aroma













Intensity
5
3











Blackcurrant
4
5
1
2
0
3
4
1
2
0
0


Alcohol
0
0
0
0
0
2
0
0
0
0
0


Mouldy
0
0
3
1
5
1
0
3
1
3
5






herbal/tea
hearth/cheesy


dusty/musty
dusty/musty
cheesy
butyric/cheesy


Taste













Sweetness
4
5
2
2
3
2
4
2
2
3
1


Sourness
3
3
1
3
2
1
3
4
2
1
1


Flavour













Blackcurrant
4.5
5
1
2
2
1
3.5
2
0
2



Fermented
0
0
0
0
0
3
0
0
1
0



Mouldy/Yeast
0
0
3
0
3
1
0
2
2
2



Herbal
0
1
4
3
0
1
0.5
2
0
0



Yoghurt/Cheese



0
3
1
0
0
1
0
5


Mouthfeel
4.5
5
1
1
3
0
2
1
1
2
3


Aftertaste













Artificialness
0
5
0
3
1
1
0
2
1
2



Linguerings
0
5
1
0
2
0
1
3
2
3



Astringency
1
2.5
3
2
1
1
1
0
1
0





















dusty
tea, candy
cherry
watery
flavour

overriped fruit
off balance





















aroma



linguering













not bad


























most balanced












too cheesy









Example 9
Screening of Fermentation Microorganisms

Small samples (50 ml) of a 60 g/L stevia infusion, prepared as described herein, were supplemented with 30 g/L sugar and then inoculated with various fermentation microorganisms and incubated in 300 ml shake flasks at 28° C. with shaking. Microbial strains were cultivated on a small scale in shake flasks, harvested after 2 days, suspended in spent medium and subsequently served as inoculum in the infusion. Duration of fermentation step was 3 days.


Harvesting was done as in example 7A.


Experimental parameters:





















resuspend in





Strain
Medium
spent medium


















Culture
Species
Strain

Sugar g/L
[ml]
Temp
rpm
Gas








50 ml Medium,










500 ml shakeflask





















MB.A1

Meyerozyma

S-III
YPD
Glucose
15
3
28° C.
180
aerobic




guilliermondii











MB.A2

Meyerozyma

S-IX
YPD
Glucose
15
3
28° C.
180
aerobic




guilliermondii











MB.A3

Meyerozyma

S-X
YPD
Glucose
15
3
28° C.
180
aerobic




guilliermondii



























150 ml Medium,










300 ml shakeflask





















MB.B

Lactobacillus

S-IV
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus











MB.C

Lactobacillus

S-IV
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus











MB.D

Lactobacillus

S-XI
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus











MB.E

Lactobacillus

S-XI
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus











MB.F

Lactobacillus

S-XII
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus











MB.G

Lactobacillus

S-XII
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus











MB.H

Lactobacillus

S-XIII
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus











MB.I

Lactobacillus

S-XIII
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus



















Infusion
Biomass
Incubation
















Bacterium
Yeast
Stevia

Suspension [μl]
Temp




















Sample
Name
Strain
Name
Strain
(g/L)
sugar [g/L]
Bacterium
Yeast
[° C.]
rpm
Gas






















MB1

Lactobacillus

S-IV

Meyerozyma

S-III
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB2

Lactobacillus

S-IV

Meyerozyma

S-IX
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB3

Lactobacillus

S-IV

Meyerozyma

S-X
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB4

Lactobacillus

S-XI

Meyerozyma

S-III
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB5

Lactobacillus

S-XI

Meyerozyma

S-IX
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB6

Lactobacillus

S-XI

Meyerozyma

S-X
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB7

Lactobacillus

S-XII

Meyerozyma

S-III
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB8

Lactobacillus

S XII

Meyerozyma

S-IX
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB9

Lactobacillus

S-XII

Meyerozyma

S-X
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB10

Lactobacillus

S-XIII

Meyerozyma

S-III
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB11

Lactobacillus

S-XIII

Meyerozyma

S-IX
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii












MB12

Lactobacillus

S-XIII

Meyerozyma

S-X
60
Sucrose
30
3000
500
37
80
anaerobic




acidophilus



guilliermondii










Analytical Results:


HPLC method I: Sugar, acid analytics

    • Column: Rezex™ ROA-Organic Acid H+(8%), 300×4.6 mm
    • Solvent A: 0.1% (v/v) trifluoroacetic acid (TFA)
    • Flow: isocratic
    • Total runtime: 30 min
    • Detection by DAD (210 nm) and RID
    • Samples are diluted 2- or 5-fold (depending on expected metabolite concentrations) with appropriate volumes of 2% (v/v) and water to a final concentration of 1% (v/v) TFA and filtered (hPTFE 0.22 μm) prior to injection
    • Injection volume: 10 μl
    • Target analytes: acetic acid, formic acid, fructose, glucose, glycerol, lactic acid and succinic acid
























Succinate
Lactate
Glycerol
Acetate





Sample #
Glucose [mM]
Fructose [mM]
[mM]
[mM]
[mM]
[mM]
pH
Brix
OD
























MB1
34.92
41.36
1.23
91.21
0.00
3.98
3.36
6.6
0.34


MB2
31.94
27.43
1.31
89.41
0.00
5.34
3.28
6.4
0.46


MB3
34.08
33.55
1.24
90.25
0.00
4.72
3.3
6.6
0.34


MB4
54.55
32.49
1.52
77.43
0.00
4.33
3.39
6.7
0.32


MB5
34.07
28.12
1.59
85.55
0.00
4.83
3.35
6.6
0.42


MB6
43.89
28.05
1.47
76.11
0.00
5.08
3.39
6.7
0.36


MB7
28.42
44.78
1.33
100.79
0.00
4.59
3.23
6.7
0.46


MB8
32.77
30.00
1.33
100.19
0.00
4.91
3.23
6.6
0.52


MB9
28.62
41.03
1.24
99.96
0.00
4.35
3.18
6.6
0.46


MB10
32.30
25.93
0.71
112.82
0.00
4.07
3.21
6.3
0.34


MB11
32.41
29.01
0.94
88.71
0.00
4.38
3.28
6.4
0.46


MB12
34.12
29.31
0.89
110.02
0.00
3.67
3.22
6.7
0.34









HPLC method II: Qualitative Steviolglycoside analytics

    • Column: Kinetex C18 2.6 μm 150*2.1 mm
    • Solvent A: 0.1% formic acid
    • Solvent B: AcN+0.1% formic acid
    • Flow: binary gradient 0.2 mlimin starting with 20%B
    • Total runtime: 54 min
    • MS detection in negative mode 300-1300 m/z
    • Samples are diluted 1:10 in mobile phase (80%A/20%B) and filtrated (hPTFE 0.22 μm) prior to injection
    • Injection volume: 10 μl
    • Analyte target: Reb E, D, M, I, A, F, C, B as well as Stevioside, Dulcoside A, Rubusoside, Steviobioside























1
2
















MB
RT

CTL


delta


delta


Analyte
[min]
Chromatogram
Area
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
21133166
33585000
12451834
58.92
23213272
2080106
9,84


RebD
15.9
EIC 1127.91 -All MS
178411712
271214240
92802528
52.02
192609712
14198000
7,96


RebM
17.8
EIC 1290.01 -All MS
95807944
169304016
73496072
76.71
107263096
11455152
11,96


Reb O
17.8
EIC 1435.93 -All MS
29082594
49154060
20071466
69.02
32391920
3309326
11,38


Reb N
18.8
EIC 1273.93 -All MS
100302256
188920432
88618176
88.35
117913872
17611616
17,56


RebI
26.2
EIC 1127.91 -All MS
42886856
80281056
37394200
87.19
49926668
7039812
16,41


RebA
26.9
EIC 965.77 -All MS
1239538560
437555648
−801982912
−64.70
1221443072
−18095488
-1,46


Stevioside
27.3
EIC 849.63 -All MS
396731136
1334060160
937329024
236.26
401947136
5216000
1,31


RebF
29.4
EIC 935.72 -All MS
206843424
374628608
167785184
81.12
233754576
26911152
13,01


RebC
30.5
EIC 949.75 -All MS
965740864
1263732736
297991872
30.86
978151680
12410816
1,29


Dulcoside A
31
EIC 833.62 -All MS
14314568
23595510
9280942
64.84
15326281
1011713
7,07


Rubusoside
32.1
EIC 687.51 -All MS
72437704
103103432
30665728
42.33
58343752
−14093952
-19,46


RebB
35.9
EIC 803.65 -All MS
222909728
399515072
176605344
79.23
270265056
47355328
21,24


Steviolbioside
36.2
EIC 641.49 -All MS
49181772
78931568
29749796
60.49
56349100
7167328
14,57

















3
4















MB
RT



delta


delta


Analyte
[min]
Chromatogram
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
31472340
10339174
48.92
22759620
1626454
7.70


RebD
15.9
EIC 1127.91 -All MS
257548000
79136288
44.36
188175568
9763856
5.47


RebM
17.8
EIC 1290.01 -All MS
147584624
51776680
54.04
116926720
21118776
22.04


Reb O
17.8
EIC 1435.93 -All MS
43392104
14309510
49.20
33291294
4208700
14.47


Reb N
18.8
EIC 1273.93 -All MS
163620384
63318128
63.13
126244232
25941976
25.86


RebI
26.2
EIC 1127.91 -All MS
loniTib
27890880
65.03
52700416
9813560
22.88


RebA
26.9
EIC 965.77 -All MS
1274696576
35158016
2.84
1191936128
−47602432
−3.84


Stevioside
27.3
EIC 849.63 -All MS
432610592
35879456
9.04
396234016
−497120
−0.13


RebF
29.4
EIC 935.72 -All MS
324349312
117505888
56.81
251034768
44191344
21.36


RebC
30.5
EIC 949.75 -All MS
1168051072
202310208
20.95
1034571648
68830784
7.13


Dulcoside A
31
EIC 833.62 -All MS
21982024
7667456
53.56
17433616
3119048
21.79


Rubusoside
32.1
EIC 687.51 -All MS
73725616
1287912
1.78
69372344
−3065360
−4.23


RebB
35.9
EIC 803.65 -All MS
355258848
132349120
59.37
286858656
63948928
28.69


Steviolbioside
36.2
EIC 641.49 -All MS
77000216
27818444
56.56
58756564
9574792
19.47

















5
6















MB
RT



delta


delta


Analyte
[min]
Chromatogram
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
29691366
8558200
40.50
20023090
−1110076
−5.25


RebD
15.9
EIC 1127.91 -All MS
246800176
68388464
38.33
170226688
−8185024
−4.59


RebM
17.8
EIC 1290.01 -All MS
136609232
40801288
42.59
92894928
−2913016
−3.04


Reb O
17.8
EIC 1435.93 -All MS
41093028
12010434
41.30
28715204
−367390
−1.26


Reb N
18.8
EIC 1273.93 -All MS
153323232
53020976
52.86
99715488
−586768
−0.58


RebI
26.2
EIC 1127.91 -All MS
62650256
19763400
46.08
41810476
−1076380
−2.51


RebA
26.9
EIC 965.77 -All MS
1248640000
9101440
0.73
1189953536
−49585024
−4.00


Stevioside
27.3
EIC 849.63 -All MS
412150688
15419552
3.89
382441440
−14289696
−3.60


RebF
29.4
EIC 935.72 -All MS
303273024
96429600
46.62
204290000
−2553424
−1.23


RebC
30.5
EIC 949.75 -All MS
1110822784
145081920
15.02
878784064
−86956800
−9.00


Dulcoside A
31
EIC 833.62 -All MS
18564422
4249854
29.69
13486525
−828043
−5.78


Rubusoside
32.1
EIC 687.51 -All MS
69059248
−3378456
−4.66
43380476
−29057228
−40.11


RebB
35.9
EIC 803.65 -All MS
339326944
116417216
52.23
233006368
10096640
4.53


Steviolbioside
36.2
EIC 641.49 -All MS
72466744
23284972
47.34
48258656
−923116
−1.88

















7
8















MB
RT



delta


delta


Analyte
[min]
Chromatogram
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
26575318
5442152
25.75
20169920
−963246
−4.56


RebD
15.9
EIC 1127.91 -All MS
232754208
54342496
30.46
183348816
4937104
2.77


RebM
17.8
EIC 1290.01 -All MS
141978624
46170680
48.19
99411608
3603664
3.76


Reb O
17.8
EIC 1435.93 -All MS
41670308
12587714
43.28
30435010
1352416
4.65


Reb N
18.8
EIC 1273.93 -All MS
156858816
56556560
56.39
108172936
7870680
7.85


RebI
26.2
EIC 1127.91 -All MS
65344568
22457712
52.37
44067180
1180324
2.75


RebA
26.9
EIC 965.77 -All MS
1281823360
42284800
3.41
1142243328
−97295232
−7.85


Stevioside
27.3
EIC 849.63 -All MS
430535840
33804704
8.52
378334688
−18396448
−4.64


RebF
29.4
EIC 935.72 -All MS
306966368
100122944
48.41
213909056
7065632
3.42


RebC
30.5
EIC 949.75 -All MS
1158836096
193095232
19.99
910271040
−55469824
−5.74


Dulcoside A
31
EIC 833.62 -All MS
18774058
4459490
31.15
14881779
567211
3.96


Rubusoside
32.1
EIC 687.51 -All MS
90684848
18247144
25.19
48337536
−24100168
−33.27


RebB
35.9
EIC 803.65 -All MS
352158208
129248480
57.98
239110448
16200720
7.27


Steviolbioside
36.2
EIC 641.49 -All MS
70024360
20842588
42.38
51668700
2486928
5.06

















9
10















MB
RT



delta


delta


Analyte
[min]
Chromatogram
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
27044714
5911548
27.97
25991984
4858818
22.99


RebD
15.9
EIC 1127.91 -All MS
227528000
49116288
27.53
229175552
50763840
28.45


RebM
17.8
EIC 1290.01 -All MS
135143184
39335240
41.06
138206864
42398920
44.25


Reb O
17.8
EIC 1435.93 -All MS
38367936
9285342
31.93
42423200
13340606
45.87


Reb N
18.8
EIC 1273.93 -All MS
140139440
39837184
39.72
150341264
50039008
49.89


RebI
26.2
EIC 1127.91 -All MS
57723868
14837012
34.60
64493716
21606860
50.38


RebA
26.9
EIC 965.77 -All MS
1215893760
−23644800
−1.91
1235655680
−3882880
−0.31


Stevioside
27.3
EIC 849.63 -All MS
403002592
6271456
1.58
414062240
17331104
4.37


RebF
29.4
EIC 935.72 -All MS
278342688
71499264
34.57
293842208
86998784
42.06


RebC
30.5
EIC 949.75 -All MS
1073526656
107785792
11.16
1125065088
159324224
16.50


Dulcoside A
31
EIC 833.62 -All MS
19572422
5257854
36.73
19836306
5521738
38.57


Rubusoside
32.1
EIC 687.51 -All MS
64959744
−7477960
−10.32
76920296
4482592
6.19


RebB
35.9
EIC 803.65 -All MS
316615904
93706176
42.04
323027328
100117600
44.91


Steviolbioside
36.2
EIC 641.49 -All MS
66637128
17455356
35.49
66778728
17596956
35.78

















11
12















MB
RT



delta


delta


Analyte
[min]
Chromatogram
Area
delta Area
Area %
Area
delta Area
Area %





RebE
14.3
EIC 965.77 -All MS
23156738
2023572
9.58
20479096
−654070
−3.09


RebD
15.9
EIC 1127.91 -All MS
207243104
28831392
16.16
174267728
−4143984
−2.32


RebM
17.8
EIC 1290.01 -All MS
119581232
23773288
24.81
99081224
3273280
3.42


Reb O
17.8
EIC 1435.93 -All MS
35129796
6047202
20.79
29828870
746276
2.57


Reb N
18.8
EIC 1273.93 -All MS
130991576
30689320
30.60
110230112
9927856
9.90


RebI
26.2
EIC 1127.91 -All MS
51848760
8961904
20.90
43290368
403512
0.94


RebA
26.9
EIC 965.77 -All MS
1204701952
−34836608
−2.81
1156384128
−83154432
−6.71


Stevioside
273
EIC 849.63 -All MS
414527328
17796192
4.49
387886144
−8844992
−2.23


RebF
29.4
EIC 935.72 -All MS
255493728
48650304
23.52
215662720
8819296
4.26


RebC
30.5
EIC 949.75 -All MS
1048821056
83080192
8.60
905791424
−59949440
−6.21


Dulcoside A
31
EIC 833.62 -All MS
16716718
2402150
16.78
14747960
433392
3.03


Rubusoside
32.1
EIC 687.51 -All MS
75089040
2651336
3.66
55947696
−16490008
−22.76


RebB
35.9
EIC 803.65 -All MS
302767328
79857600
35.83
238574176
15664448
7.03


Steviolbioside
36.2
EIC 641.49 -All MS
64069524
14887752
30.27
49876788
695016
1.41









Sensory results:


Fermented samples were applied in a beverage composition as follows:

    • Prepare a concentrated base of the drink that will be diluted 1:4 (1 part of base for 4 parts of water).
    • Add the ingredient at 10 g/L
    • Top up with the remaining part of water.
    • Apple/Cherry drink:
    • BASE INGREDIENTS:
    • Ingredients: Water, Sugar, Fruit juices from concentrates 5% (Apple, Cherry), Natural flavourings (Apple, Cherry), Acids (Citric acid, Ascorbic acid), Acidity regulator (Sodium gluconate), Colour (extracts of carrot, hibiscus), Sweetener (Steviol glycosides)


Fermented samples were tasted by a trained expert comparing samples to an internal benchmark.
















Description on




overall flavour


Sample #
Description on sweetness
impression







MB1
Clean sweetness, no lingering
floral notes, fruity, clean,



aftertaste, reduced
similar sweetness



bitterness from Stevia
and mouthfeel, drying




aftertaste


MB2
Clean sweetness, no lingering
Drying, bland, clean



aftertaste, reduced




bitterness from Stevia



MB3
Clean sweetness, no lingering
Bland, clean, watery



aftertaste, reduced




bitterness from Stevia



MB4
Clean sweetness, no lingering
Clean,fruity, less



aftertaste, reduced
mouthfeel



bitterness from Stevia



MB5
Clean sweetness, no lingering
Clean, drying, watery



aftertaste, reduced




bitterness from Stevia



MB6
Clean sweetness, no lingering
Fruity, clean, similar



aftertaste, reduced
mouthfeel and



bitterness from Stevia
sweetness


MB7
Clean sweetness, no lingering
Floral tea notes,



aftertaste, reduced
similar sweetness



bitterness from Stevia
and mouthfeel


MB8
Clean sweetness, no lingering
Clean, fruity, similar



aftertaste, reduced
sweetness and



bitterness from Stevia
mouthfeel


MB9
Clean sweetness, no lingering
Clean,fruity, less



aftertaste, reduced
mouthfeel



bitterness from Stevia



MB10
Clean sweetness, no lingering
Bland, clean



aftertaste, reduced




bitterness from Stevia



MB11
Clean sweetness, no lingering
Sour, bland, clean



aftertaste, reduced




bitterness from Stevia



MB12
Clean sweetness, no lingering
Bland, clean



aftertaste, reduced




bitterness from Stevia









Example 10
Screening of Fermentation Microorganisms

Small samples (50 ml) of a 60 g/L stevia infusion, prepared as described herein, were supplemented with 30 g/L sugar and then inoculated with various fermentation microorganisms and incubated in 300 ml shake flasks. Microbial strains were cultivated on a small scale in shake flasks, harvested after 2 days, suspended in spent medium and subsequently served as inoculum in the infusion. Duration of fermentation step was 3 days. Harvesting was done as in example 7A.


Experimental parameters:





















resuspend in





Strain
Medium
spent


















Culture
Species
Strain

Sugar g/L
medium [ml]
Temp
rpm
Gas






















30 ml Medium,











300 ml shakeflask








MC.A1

Pichia

S-I
YPD
Glucose
15
3
28° C.
180
aerobic




membranifaciens











MC.A2

Cyberlindnera

S-II
YPD
Glucose
15
3
28° C.
180
aerobic




jadinii











MC.A3

Meyerozyma

S-III
YPD
Glucose
15
3
28° C.
180
aerobic




guilliermondii



























150 ml Medium,










300 ml shakeflask





















MC.B

Lactobacillus

S-IV
MRS
Glucose
20
5
37° C.
0
anaerobic




acidophilus











MC.C

Lactobacillus

S-V
MRS
Glucose
20
5
37° C.
0
anaerobic




delbrueckii














50 ml Medium,











500 ml shakeflask








MC.D

Lactobacillus

S-VI
MRS
Glucose
20
1.5
37° C.
0
anaerobic




fructivorans











MC.E

Lactobacillus

S-VI
MRS
Glucose
20
1.5
37° C.
0
anaerobic




fructivorans











MC.F

Lactobacillus

S-VI
MRS
Glucose
20
1.5
37° C.
0
anaerobic




fructivorans











MC.G

Lactobacillus

S-VI
MRS
Glucose
20
1.5
28° C.
180
aerobic




fructivorans











MC.H

Lactococcus

S-VIII
MRS
Glucose
20
1.5
28° C.
180
aerobic




raffinolactis











MA.D3


MRS
Glucose
20
1.5
28° C.
180
aerobic


MA.E1


MRS
Glucose
20
2
28° C.
180
aerobic


MA.E2


MRS
Glucose
20
2
28° C.
180
aerobic


MA.F1


MRS
Glucose
20
2
28° C.
180
aerobic


MA.F2


MRS
Glucose
20
2
28° C.
180
aerobic


















Infusion
Biomass
Incubation
















Bacterium
Yeast
Stevia

Suspension [μl]
Temp




















Sample
Name
Strain
Name
Strain
(g/L)
sugar [g/L]
Bacterium
Yeast
[° C.]
rpm
Gas






















MC1

Lactobacillus

S-IV


60
Sucrose
30
2000

37
80
anaerobic




acidophilus














MC2

Lactobacillus

S-V


60
Sucrose
30
2000

37
80
anaerobic




delbrueckii














MC3

Lactobacillus

S-VI


60
Sucrose
30
2000

28
80
aerobic




fructivorans














MC4

Lactobacillus

S-IV

Pichia

S-I
60
Sucrose
30
1000
200
37
80
anaerobic




acidophilus



membranifaciens












MC5

Lactobacillus

S-V

Pichia

S-I
60
Sucrose
30
1000
200
37
80
anaerobic




delbrueckii



membranifaciens












MC6

Lactobacillus

S-VI

Pichia

S-I
60
Sucrose
30
1000
200
28
80
aerobic




fructivorans



membranifaciens












MC7

Lactobacillus

S-IV

Cyberlindnera

S-II
60
Sucrose
30
1000
200
37
80
anaerobic




acidophilus



jadinii












MC8

Lactobacillus

S-V

Cyberlindnera

S-II
60
Sucrose
30
1000
200
37
80
anaerobic




delbrueckii



jadinii












MC9

Lactobacillus

S-VI

Cyberlindnera

S-II
60
Sucrose
30
1000
200
28
80
aerobic




fructivorans



jadinii












MC10

Lactobacillus

S-V

Meyerozyma

S-III
60
Sucrose
30
1000
200
37
80
anaerobic




delbrueckii



guilliermondii












MC11

Lactobacillus

S-VI

Meyerozyma

S-III
60
Sucrose
30
1000
200
28
80
aerobic




fructivorans



guilliermondii












MC12

Lactococcus

S-VIII

Meyerozyma

S-III
60
Sucrose
30
1000
200
37
80
anaerobic




raffinolactis



guilliermondii










Analytical results:


HPLC method I: Sugar, acid analytics

    • Column: Rezex™ ROA-Organic Acid H+(8%), 300×4.6 mm
    • Solvent A: 0,1% (v/v) trifluoroacetic acid (TFA)
    • Flow: isocratic
    • Total runtime: 30 min
    • Detection by DAD (210 nm) and RID
    • Samples are diluted 2- or 5-fold (depending on expected metabolite concentrations) with appropriate volumes of 2% (v/v) and water to a final concentration of 1% (v/v) TFA and filtered (hPTFE 0.22 μm) prior to injection
    • Injection volume: 10 μl
    • Target analytes: acetic acid, formic acid, fructose, glucose, glycerol, lactic acid and succinic acid






















Glucose
Fructose
Succinate
Lactate
Glycerol
Acetate





Sample #
[mM]
[mM]
[mM]
[mM]
[mM]
[mM]
PH
Brix
OD
























MC1
95.05
86.73
1.38
62.31
0.00
4.30
3.25
6
0.19


MC2
79.24
83.88
1.09
58.99
0.00
4.03
3.23
5.8
0.21


MC3
40.79
33.80
0.00
57.45
2.43
47.43
3.11
5.2
0.25


MC4
89.89
87.60
1.61
52.46
0.00
0.00
3.22
5.8
0.26


MC5
87.19
94.16
1.35
46.59
0.00
0.00
3.28
5.8
0.27


MC6
33.25
53.62
0.00
47.69
1.95
41.23
3.11
4.8
0.28


MC7
0.16
0.71
4.50
20.52
17.57
4.59
3.39
3.2
0.23


MC8
0.24
0.33
4.23
24.31
17.35
7.20
3.42
3.2
0.27


MC9
0.83
0.00
1.47
22.42
10.48
26.09
3.4
3.5
0.3


MC10
95.74
105.25
1.03
41.25
0.00
0.00
3.35
5.9
0.31


MC11
0.49
0.00
0.00
56.27
6.29
69.49
3.02
4.4
0.25


MC12
96.07
102.37
0.67
6.44
0.24
0.00
4.43
5.8
0.23









Sensory Results (Trained Expert):


Fermented samples were applied in a beverage composition as follows:

    • Prepare a concentrated base of the drink that will be diluted 1:4 (1 part of base for 4 parts of water).
    • Add the ingredient at 10 g/L
    • Top up with the remaining part of water.
    • Apple/Cherry drink:
    • BASE INGREDIENTS:
    • Ingredients: Water, Sugar, Fruit juices from concentrates 5% (Apple, Cherry), Natural flavourings (Apple, Cherry), Acids (Citric acid, Ascorbic acid), Acidity regulator (Sodium gluconate), Colour (extracts of carrot, hibiscus), Sweetener (Steviol glycosides)


Fermented samples were tasted by a trained expert comparing samples against an internal benchmark
















Sample #
Description on sweetness









MC1
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC2
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC3
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC4
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC5
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC6
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC7
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC8
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC9
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC10
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC11
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia



MC12
Clean sweetness, no lingering aftertaste,




reduced bitterness from Stevia










Example 11

To explore the utility of the ingredient of the invention as a sweetening ingredient for food (e.g. shortbread) the following trial was carried out.


The objective is to understand consumer perception and the main differences between four shortbreads:


Full sugar (shortbread A)


Half sugar +fermented stevia infusion according to the invention (shortbread B)


Half sugar +unfermented stevia infusion (shortbread C)


Half sugar +Reb A (shortbread D)


Ingredients:


1 kg of each shortbread batch was made according to the recipes below (amounts in wt %):




















A
B
C
D









Butter
45
45
45
45



Flour
30
30
30
30



Sugar
20
10
10
10



Polydextrose

10
10
10



Fermented stevia infusion

 5.7





Unermented stevia infusion


 5.7




Reb A



 0.045



Water
 5


 5










Erythritol formulas were used to determine equivalent amounts of each sweetener to achieve the same theoretical sweetness.


All doughs were rolled out to approximately 1 cm in thickness and 5 cm in diameter and cooked in an oven at 160° C. for 25 minutes.


Cookies were cooled and packaged up to be sent to participants for tasting.


Method:

    • A total of 11 people evaluated the samples in an online test.
    • Participants assessed samples following a questionnaire about their personal taste and perception, being a subjective methodology.
    • Data was captured on an online survey application, and then analysed with XLSTAT.
    • For each question, statistical analysis of data through ANOVA and multiple range test (LSD) distributed products into different groups (identified with alphabetic letters) according to the sequential order and the significant differences among samples means.
    • All differences referred to are significant at 95% confidence level.


No significant difference was found between the samples for overall liking and taste liking.


Exemplary sensory results (JAR questions) are shown in FIG. 9.


Appearance: B and D are very similar. The other samples are lighter in colour


Overall flavor: B is the least intense


Sweetness: B and A are perceived similarly in sweetness (Just-About-Right).


Bitterness: D is the most bitter.


Overall texture: D is the driest and A is Just-About-Right.


Crispiness: D is the crispiest. A and C are perceived similarly.


Lingering aftertaste (AT): C is slightly more lingering than the other samples.

Claims
  • 1. An ingredient based on a fermented infusion of stevia, wherein the infusion has been fermented using a combination of at least two different microorganisms.
  • 2. An ingredient according to claim 1, wherein the infusion has been fermented using a combination of at least one yeast and at least one bacteria.
  • 3. An ingredient according to claim 2, wherein the yeast is selected from Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxianus, Zygosaccharomyces rouxii, Pichia membranifaciens, Cyberlindnera jadinii, and Meyerozyma guilliermondii.
  • 4. An ingredient according to claim 2, wherein the yeast is Meyerozyma guilliermondii.
  • 5. An ingredient according to claim 2, wherein at least one bacteria is a lactic-acid producing bacteria, preferably of the Lactobacillus genus, more preferably selected from L. acidophilus, L. fructivorans, L. gasseri, L. jensenii, L. delbrueckii, L. delbrueckii subsp. bulgaricus, L. amylovorus, L. crispatus, and L. helveticus.
  • 6. An ingredient according to claim 2, wherein at least one bacteria is Lactobacillus acidophilus.
  • 7. An ingredient according to claim 1, wherein fermentation with each microorganism takes place sequentially.
  • 8. An ingredient according to claim 1, wherein fermentation with each microorganism takes place simultaneously.
  • 9. An ingredient comprising a fermented infusion of stevia, wherein the infusion is fermented by a microorganism selected from yeast and bacteria, or a combination thereof, wherein the fermented infusion is prepared by contacting uncured stevia leaves with water to produce an infusion, then adding a fermentation microorganism to said infusion.
  • 10. An ingredient according to claim 1, wherein the sweetening ingredient has a taste and sensory profile which is modified and/or improved as a result of the fermentation, when compared to an unfermented stevia infusion.
  • 11. An ingredient according to claim 9, wherein the infusion is fermented using yeast, for example a yeast selected from Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxianus, Zygosaccharomyces rouxii, Pichia membranifaciens, Cyberlindnera jadinii, and Meyerozyma guilliermondii.
  • 12. An ingredient according to claim 9, wherein the infusion is fermented using bacteria, for example a lactic acid producing bacterium.
  • 13. An ingredient according to claim 9, wherein the infusion is fermented using more than one microorganism, wherein fermentation with each microorganism takes place either sequentially or simultaneously.
  • 14. An ingredient according to claim 13, wherein the infusion is fermented using a combination of one or more yeasts with one or more bacteria.
  • 15. An ingredient according to claim 1, wherein the microorganism or combination of microorganisms is selected to provide a pre-determined sensory and/or taste profile in the fermented infusion.
  • 16. An ingredient according to claim 1, wherein the fermented infusion is prepared by contacting stevia with water to produce an infusion, then adding the microorganism directly to said infusion to perform the fermentation.
  • 17. An ingredient according to claim 1 wherein the infusion is produced by heating, preferably at a temperature below about 90° C., more preferably at a temperature below 85° C., more preferably at a temperature of 50-70° C.
  • 18. An ingredient according to claim 1, wherein the stevia comprises plant material from Stevia rebaudiana, Stevia phlebophylla, Rubus chingii, Rubus suavissimus or Siraitia grosvenorii.
  • 19. An ingredient according to claim 1, wherein the stevia comprises plant material from Stevia rebaudiana.
  • 20. An ingredient according to claim 1 wherein the fermented infusion has a modified steviol glycoside composition compared to the unfermented infusion.
  • 21. (canceled)
  • 22. (canceled)
  • 23. An ingredient comprising an aqueous solution of steviol glycosides, having: a pH from about 3.1 to about 3.9;an OD600 from about 0.15 to 0.8;a lactate content from about 0 to about 10 g/L; andan acetate content from about 0 to about 2.5 g/L.
  • 24. An ingredient according to claim 23, wherein the ingredient comprises at least 100 μm steviol glycosides in solution.
  • 25. (canceled)
  • 26. An ingredient according to claim 23 wherein the ingredient is obtainable by or obtained by a process involving fermention of a stevia infusion.
  • 27. A process for preparing an ingredient comprising a fermented infusion of stevia, said process comprising the steps of: (a) contacting stevia with water and optionally heating to produce an infusion;(b) optionally adding carbohydrate or a carbohydrate source to the infusion;(c) optionally filtering the infusion to remove remaining stevia;(d) adding a fermentation microorganism to the infusion;(e) fermenting the infusion under conditions suitable to the microorganism, to produce a fermented infusion.
  • 28. A process according to claim 27, wherein step (a) comprises heating at a temperature of 40-90° C.
  • 29. A process according to claim 27, wherein in step (a) the duration of the infusion step is from 15 to 45 minutes.
  • 30. A process according to claim 27, wherein the carbohydrate added in step (b) is sugar and the total amount of sugar at the start of the fermentation step is from 30-50 g/L (3-5 Bx).
  • 31. A process according to claim 27, wherein the microorganism used for the fermentation is selected from yeast or bacteria, or a combination thereof.
  • 32. A process according to claim 31, wherein the microorganism used for the fermentation step comprises a yeast selected from Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxianus, Zygosaccharomyces rouxii, Pichia membranifaciens, Cyberlindnera jadinii, and Meyerozyma guilliermondii.
  • 33. A process according to claim 31, wherein the microorganism used for the fermentation step comprises bacteria.
  • 34. A process according to claim 27, wherein the microorganism used for the fermentation is selected to provide a pre-determined sensory and/or taste profile in the fermented infusion.
  • 35. (canceled)
  • 36. (canceled)
  • 37. (canceled)
  • 38. Use of a sweetening ingredient according to claim 1, in the production of a food or beverage product.
  • 39. A food or beverage product comprising a sweetening ingredient according to claim 1.
  • 40. (canceled)
  • 41. (canceled)
  • 42. (canceled)
Priority Claims (1)
Number Date Country Kind
2002078.0 Feb 2020 GB national
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2021/053670 2/15/2021 WO